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 A number of new biosynthetic gene clusters encoding phosphonate natural products have 
been characterized by mining of microbial genomes. Phosphonates, which are characterized by 
their hydrolytically stable carbon-phosphorus bond, are prevalent in everyday life, such as in 
commercially available herbicides and an antibiotic deemed critically important in the clinic. 
Their biosynthetic pathways are rich in novel chemistry, ranging from iron-dependent radical 
rearrangements to multiple methods of forming amide bonds. This thesis will include my 
contributions to understanding phosphonate enzymatic chemistry in more detail.  
 Methylphosphonate (MPn) was recently isolated from marine surface waters and is 
proposed to be a precursor in the production of methane, which is supersaturated in these 
environments. The oxygenase MPn synthase (MPnS) produces MPn from 2-
hydroxyethylphosphonate (2-HEP), a substrate also acted on by 2-HEP dioxygenase (HEPD) to 
make hydroxymethylphosphonate (HMP). Both enzymes are proposed to share a common 
mechanism up until the final intermediate consisting of an MPn radical and formate. Chapter 2 
will discuss efforts to elucidate how each enzyme dictates individual product formation at this 
key branching step between the two mechanisms. An unprecedented 2-His-1-Gln facial triad, 
along with the identity of a second sphere residue, were determined to contribute to MPn versus 
HMP formation. This sequence motif was used to predict the prevalence of MPnS in other 
microbial genomes, leading to the functional characterization of an MPnS from the abundant 
marine bacterium Pelagibacter ubique. This discovery further supports MPn as a possible source 
of the supersaturated methane levels in the aerobic ocean. 
 The tripeptide antibiotic dehydrophos consists of a phosphonate warhead attached to two 
proteinogenic amino acids which function to allow entry into target cells. During biosynthesis, 
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these amino acids are transferred to the phosphonate through the action of aminoacyl-tRNA (aa-
tRNA)-dependent ligases. Chapter 3 will discuss efforts to characterize the interaction of the 
enzyme DhpH-C with Leu-tRNALeu. Mutagenesis studies of both the enzyme and tRNA led to 
the conclusion that DhpH-C shares features of aa-tRNA recognition common to other aa-tRNA-
dependent enzymes. In addition, DhpH-C was found to accept other amino acids for the 
production of multiple dipeptide phosphonates, although Leu-tRNALeu was the most efficient 
substrate with the fastest rate of product formation over time. These features of DhpH-C may aid 
in future studies to produce phosphonate analogs chemoenzymatically, and its modes of aa-
tRNA substrate recognition appear to be applicable to the study of aa-tRNA-dependent enzymes 
in the production of different natural product classes. 
 Biosynthesis of the clinically used antibiotic fosfomycin can occur by two convergent 
routes in Streptomyces and Pseudomonas species. The pathways only share the first and last 
steps, which are catalyzed by phosphoenolpyruvate mutase and 2-hydroxypropylphosphonate 
epoxidase (HppE), respectively. Chapter 4 will discuss efforts to elucidate the more recently 
discovered pathway in Pseudomonas syringae PB-5123. Analysis of the gene cluster led to the 
characterization of reductase Psf3 as the penultimate step converting 2-oxopropylphosphonate 
(2-OPP) to (S)-2-hydroxypropylphosphonate ((S)-2-HPP). Active site mutants were analyzed for 
activity to probe how Psf3 interacts with 2-OPP and performs its stereospecific reduction. 
Combining our investigation of Psf3 with the previous characterization of Psf4 (HppE) led to the 
formulation of a one-pot assay to produce fosfomycin from racemic 2-HPP. Further elucidation 
of the fosfomycin pathway in P. syringae should uncover new biosynthetic mechanisms in 
phosphonate metabolism and provide insight into how two almost completely different sets of 
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Chapter 1: Introduction 
 
1.1 GENOME MINING FOR NOVEL NATURAL PRODUCTS AND ENZYMATIC 
CHEMISTRY 
 From catalogs of medicinal plants in Mesopotamian records to the use of egg whites to 
treat wounds mentioned in Shakespeare’s plays, we can trace the use of natural products to 
alleviate ailments back through countless generations.1,2 Whether it is for the treatment of cancer, 
infections, or other illnesses, natural products or compounds inspired by them currently account 
for 2/3 of our medicinal repertoire.3 Therefore, understanding the origin of these compounds and 
how to discover new varieties is critical for our community to stay abreast of disease-causing 
agents. The explosion in genomic data in the last couple of decades has fueled our ability to 
connect the organisms that manufacture natural products with how they accomplish such diverse 
chemical reactions to form these metabolites. The discovery of novel natural products is a 
particularly salient issue considering the rise in drug-resistant bacteria.4 Genome sequencing has 
provided the scientific community with a surplus of information that can be mined for likely 
producers of new classes of compounds and compounds with unique modes of action, two 
crucial criteria to meet in the drug discovery process to revitalize the utility of natural products as 
medicines.5  
 Microbes from the class Actinobacteria are significant producers of natural products.6 
Sequencing of the Streptomyces coelicolor genome in 20027 led to a new investment in the 
discovery of metabolites produced by these species. Within bacteria, genes needed for the 
production of a given natural product are generally clustered together in the genome in a 
biosynthetic gene cluster. The sequencing of Streptomyces genomes revealed that they contain 
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many more biosynthetic gene clusters than the number of characterized natural products.6 This 
wealth of information stimulated the field of genome mining, a term that can encompass a 
number of scientific endeavors. For this thesis, genome mining refers to searching for 
biosynthetic gene clusters of interest to identify novel natural products.8,9 Genome sequencing 
provided the map for setting out on discovery expeditions. However, additional work is 
necessary to develop a genome mining compass and a legend to reliably predict whether a 
biosynthetic gene cluster will produce a natural product of interest. 
 Natural products are generally grouped based on common functional groups or 
biosynthetic origins. Therefore, common enzymes encoded in the biosynthetic gene cluster that 
catalyze the formation of certain scaffolds can be used to group gene clusters. Numerous families 
of enzymes are known to form certain functional groups, and they have been used as a compass 
to steer researchers toward gene clusters of interest. Examples include post-translational 
modification enzymes of ribosomally synthesized peptide natural products,10,11 the large 
megasynthases and their individual domains responsible for the assembly line production of non-
ribosomal peptides and polyketides,12,13 and terpene synthases for the biosynthesis of terpenoid 
natural products in bacteria.14 Multiple bioinformatics programs have been developed to search 
for gene clusters in silico based on representative encoded peptides/enzymes, such as 
antiSMASH,15 PRISM,16,17 and RODEO.18  
 Follow-up studies are then needed to decipher the chemical logic encoded in a gene 
cluster once one is chosen for analysis. In other words, information about the types of chemical 
reactions associated with different genes needs to be compiled to create a gene cluster legend to 
sketch out the potential final natural product. In conjunction with natural product structure 
determination, studying biosynthetic enzymes found from genome mining expeditions has also 
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unearthed novel enzymatic chemistry. Some select reviews cover this topic in more depth.19,20 
Examples include multiple mechanisms of methylation by radical S-adenosyl-L-methionine 
(SAM) enzymes21,22 and an expansion of functions for the SAM cofactor.23,24 Taken together, 
mechanistic studies on individual biosynthetic enzymes extend the library of biochemical 
knowledge to be accessed every time researchers aim to decipher a new gene cluster. 
 Phosphonate natural products have been studied through genome mining efforts, with 
gains made in novel compound determination and the examination of new biosynthetic 
chemistry.25 The next sections will introduce the phosphonate class of compounds and their 
benefits to society, their biosynthesis, and a large-scale effort to probe their diversity in nature. 
My thesis consists of three projects that have all originated from this extensive endeavor to cover 
phosphonate biosynthetic space. 
 
1.2 DIVERSITY OF PHOSPHONATE NATURAL PRODUCTS AND THEIR MODES 
OF ACTION 
Synthetic and biologically produced phosphonates have been key to our arsenal of 
compounds for the improvement of agricultural methods and therapeutics for decades.26 For 
example, glyphosate, a synthetic phosphonate, was developed by Monsanto as the essential 
component of the prominently used herbicide Roundup®. The naturally produced 
phosphinothricin from various Streptomyces species is also used as a popular herbicide 
(glufosinate in Liberty® and Basta®) in conjunction with genetically modified crops that carry 
the resistance gene to the phosphonate. Phosphonates and phosphinates are characterized by their 
hydrolytically stable carbon-phosphorus bond(s), which allows them to mimic carboxylic acids 
and phosphate esters to inhibit a number of critical metabolic enzymes.26 For example, 
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glyphosate acts as a mimic of phosphoenolpyruvate (PEP, Figure 1.1) to inhibit 5-
enolpyruvylshikimate-3-phosphate synthase of the shikimic acid pathway to aromatic amino 
acids. Phosphinothricin mimics the tetrahedral intermediate formed during the reaction of 
glutamine synthase (Figure 1.1). In plants, this leads to the toxic build up of ammonia. 
 
Figure 1.1 Examples of phosphonate synthetic and natural products with modes of action useful 
to society. The primary metabolites they mimic are indicated in black. APPA: (Z)-L-2-amino-5-
phosphono-3-pentenoic acid. Figure adapted from Horsman and Zechel.26 
 
 Phosphonates also function as potent antimicrobial agents. Fosfomycin, which was 
isolated from Streptomyces species in the 1960s,27 is branded under the name Monurol® and 
used to treat urinary tract infections. Fosfomycin is also a mimic of PEP (Figure 1.1) and inhibits 
enolpyruvyl transferase in cell wall biosynthesis. This unique mode of action makes fosfomycin 
a prime antibiotic for use in combination therapy with other drugs that have more common 
targets such as the transpeptidases and transglycosylases at the tail end of constructing the cell 
wall.28 Additionally, FR-900098, another phosphonate discovered from the Streptomyces genus, 















































































 A prominent subset of phosphonates is the phosphonopeptides, several of which exhibit 
antimicrobial activity. Figure 1.2 highlights the various phosphonate warheads that are attached 
to several different amino acids. Fosfazinomycin and rhizocticin have antifungal activity, 
whereas dehydrophos, plumbemycin, and phosphinothricin tripeptide (PTT) are 
antibacterials.26,29 Phosphonopeptides are classified as having a ‘Trojan horse’ mode of action. 
The peptide portion is important for entry into the target organism through generic oligopeptide 
uptake systems as possible nutrients, disguising the potent phosphonate inhibitor.30,31 Internal 
peptidases cleave off the proteinogenic amino acids, revealing the phosphonate antimicrobial. As 
with the compounds already discussed, the phosphonate moiety is critical for their mode of 
action as it mimics part of a natural metabolite. The (Z)-L-2-amino-5-phosphono-3-pentenoic 
acid (APPA) element of rhizocticin and plumbemycin mimics homoserine phosphate, resulting 
in inhibition of threonine synthase (Figure 1.1). For dehydrophos, 1-aminovinylphosphonate is 
the warhead, which is hydrolyzed to methyl acetylphosphonate to function as a mimic of 
pyruvate (Figure 1.1).  
 Phosphonates are also found in nature in an entirely different context; they can be 
attached as decorations to large macromolecules to increase their stability. In turn, these 
macromolecules serve as a nutrient source of phosphorus for other organisms. The first naturally 
occurring phosphonate discovered was 2-aminoethylphosphonate (2-AEP) as part of a 
phosphonolipid in a rumen protozoan.32 Methylphosphonate (MPn), 2-hydroxyethylphosphonate 
(2-HEP), and hydroxymethylphosphonate (HMP) were recently found to be present as 
polysaccharide esters in the dissolved organic matter fraction of surface waters from the North 
Pacific Ocean.33 Phosphonates are thought to be a key functional group for global phosphorus 
cycling in the surface waters of the ocean, as 10-15% of the phosphorus content in this 
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environment is estimated to exist as a phosphonate.34 Lipid, glycoprotein, and polysaccharide-
containing phosphonates have already been discovered from species across the tree of life, from 
humans to fungi to snails to jellyfish to bacteria.26 Recent work to classify the diversity of 
phosphonates found in microbes through the analysis of genomic sequences determined that 
roughly half of the gene clusters predicted to encode for a phosphonate are also predicted to be 
involved in lipid biosynthesis.35 For a comprehensive overview of the plethora of 
macromolecular phosphonates, I direct the reader to a recent review.26 
 
1.3 PHOSPHONATE BIOSYNTHESIS 
Almost all known phosphonates originate from the glycolysis intermediate 
phosphoenolpyruvate (PEP), which is converted to phosphonopyruvate (PnPy) by 
phosphoenolpyruvate mutase (PepM), a member of the isocitrate lyase superfamily. The 
mechanism is considered to be an unusual dissociative process involving metaphosphate as an 
intermediate.36 This C-P bond forming enzyme was only discovered in the last few decades, 
given the difficulties in studying a reaction with an equilibrium that highly favors the 
reactants.37,38 Phosphonate biosynthesis is then often driven forward by PnPy decarboxylase to 
form phosphonoacetaldehyde (PnAA). In some of the discovered pathways, PnPy is acetylated 
instead by a homolog of homocitrate synthase to make phosphonomethylmalate (Pmm).29 
Common steps after the formation of PnAA are reduction to afford 2-HEP or transamination to 
yield 2-AEP. These early common intermediates serve as the branching points for a number of 




Figure 1.2 A diagram of phosphonate biosynthetic routes. Phosphonate biosynthesis generally 
proceeds through shared initial steps starting from PEP. The only known exceptions are in the 
top left corner. Proteinogenic amino acids are highlighted in blue to emphasize the prevalence of 
phosphonopeptides in this class of natural products. Figure adapted from Peck and van der 
Donk.25 
 
The order of enzymatic operations leading from these common intermediates to the final 
product requires continued investigation for a number of the pathways in Figure 1.2. An example 
of the success of combining biochemistry, genetics, and structural biology in clarifying elusive 
steps in a biosynthetic pathway is displayed by past work in the Metcalf, Nair, and van der Donk 
laboratories on PTT.39,40 Before these studies, the middle steps of the pathway after formation of 
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been assigned a function. By systematically deleting genes expected to be involved immediately 
after PnAA formation, the authors analyzed the intermediates that accumulated to determine 
these previously missing structures. In vitro assays with purified enzyme and substrate confirmed 
the suspected reactions. Finally, after determining that an unprecedented carbon-carbon bond 
cleavage step is catalyzed by one of the previously unassigned gene products, a crystal structure 
helped classify the enzyme as a member of a large family of iron-dependent oxygenases (see 
Chapter 2 for further discussion).40 
 
1.4 GENOME MINING EFFORTS TO DISCOVER NOVEL PHOSPHONATES AND 
NEW BIOSYNTHETIC CHEMISTRY 
 An extensive effort to identify novel phosphonate natural products using our knowledge 
of phosphonate biosynthesis was spearheaded by the Metcalf laboratory. Dr. Kou-San Ju and 
coworkers analyzed 10,000 actinomycetes for the presence of pepM.41 Almost all known 
phosphonates are biosynthesized from PEP, so the pepM gene was used as the compass to locate 
likely phosphonate-producing gene clusters. Of the 10,000 genomes analyzed, 278 contained a 
likely pepM, 192 of these gene clusters had not been discovered before, and 45 out of a set of 
244 pepM+ strains showed signs of phosphonate production in the laboratory.41 The set of 278 
gene clusters was also broken down based on the gene neighborhood surrounding pepM, with the 
gene clusters splitting into 64 groups of diverse gene neighbors. These gene neighbors provided 
the legend for predicting the final natural product structure of some novel compounds. For 
example, initial screening of the phosphonate producers resulted in the discovery of argolaphos, 
a new phosphonopeptide with antibacterial activity produced by Streptomyces monomycini 
NRRL B-24309 (Figure 1.2).41 Based on the common genes shared with other phosphonate 
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pathways, the biosynthesis of argolaphos was predicted to proceed through 2-HEP.  Other genes 
in the pathway encode for predicted amide bond-forming enzymes, which helped to establish the 
structure of argolaphos as a phosphonopeptide. The Metcalf, van der Donk, and Zhao 
laboratories also applied the same technique of using pepM to identify phosphonate gene clusters 
to determine how already discovered phosphonates are biosynthesized. These studies resulted in 
initial pathway construction for dehydrophos,42 rhizocticin,43 and fosfomycin,44-46 to name a few. 
 
1.5 SUMMARY AND OUTLOOK 
 The extensive genome mining effort to uncover novel phosphonates and the biosynthetic 
pathways of known phosphonates using pepM resulted in a large source of untapped data to 
interrogate nature’s enzymatic toolbox. My thesis will discuss three independent stories ranging 
in scale from pathway reconstruction to substrate positioning in an enzyme active site. The first 
project involves two homologous non-heme iron-dependent oxygenases that use 2-HEP as a 
substrate but catalyze the formation of separate products. Previous members of the van der Donk 
laboratory have proposed a similar mechanism for the enzymes with a branch point at the last 
intermediate, which is acted on by each enzyme to afford its own product.47-49 This proposal 
raises the question of how each active site controls its reactivity on the last common intermediate 
for specific product formation. In Chapter 2, efforts in structural biology, biochemistry, and 
bioinformatics are discussed to provide a mechanistic proposal for predicting product formation. 
Second, previous efforts by former van der Donk laboratory member Dr. Despina 
Bougioukou unveiled an aminoacyl-tRNA (aa-tRNA)-dependent enzyme involved in the 
biosynthesis of the phosphonopeptide dehydrophos.50 The enzyme DhpH-C uses Leu-tRNALeu to 
attach Leu to a phosphonate derivative of Ala. DhpH-C is a member of a small group of natural 
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product biosynthetic enzymes that utilize aa-tRNA. Several of these enzymes have different 
structural folds, yet their interaction with aa-tRNA may be similar. My goal was to characterize 
the substrate specificity of DhpH-C in relation to the amino acid and recognition elements of the 
tRNA. Chapter 3 discusses the determination that DhpH-C recognizes other hydrophobic amino 
acids and elements of the acceptor stem of tRNALeu for activity. Recognition of the acceptor stem 
appears to be a shared trait with other aa-tRNA-dependent enzymes in antibiotic 
biosynthesis.51,52 
 Finally, the biosynthesis of the clinically used antibiotic fosfomycin will be discussed. 
Fosfomycin is produced by both Streptomyces and Pseudomonas species, but surprisingly, the 
gene cluster found in Pseudomonas syringae PB-5123 differs from the original gene cluster 
discovered in Streptomyces species.44,45 The order of operations in the biosynthetic pathway in 
Pseudomonas is not known apart from the first and last steps. Chapter 4 explores the elucidation 
of the penultimate step in the pathway catalyzed by Psf3, a NADPH-dependent reductase.  
 
1.6 REFERENCES 
 (1) Atanasov, A. G.; Waltenberger, B.; Pferschy-Wenzig, E. M.; Linder, T.; 
Wawrosch, C.; Uhrin, P.; Temml, V.; Wang, L.; Schwaiger, S.; Heiss, E. H.; Rollinger, J. M.; 
Schuster, D.; Breuss, J. M.; Bochkov, V.; Mihovilovic, M. D.; Kopp, B.; Bauer, R.; Dirsch, V. 
M.; Stuppner, H. Discovery and resupply of pharmacologically active plant-derived natural 
products: A review. Biotechnol. Adv. 2015, 33, 1582. 
 (2) Barber, M. F.; Elde, N. C. Buried treasure: evolutionary perspectives on microbial 
iron piracy. Trends. Genet. 2015, 31, 627. 
 (3) Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs from 1981 
to 2014. J. Nat. Prod. 2016, 79, 629. 
 (4) Worldwide country situation analysis: response to antimicrobial resistance; 
WHO Press: Geneva, Switzerland, 2015.  
11 
 
 (5) Silver, L. L. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 2011, 24, 
71. 
 (6) Katz, L.; Baltz, R. H. Natural product discovery: past, present, and future. J. Ind. 
Microbiol. Biotechnol. 2016, 43, 155. 
 (7) Bentley, S. D.; Chater, K. F.; Cerdeno-Tarraga, A. M.; Challis, G. L.; Thomson, 
N. R.; James, K. D.; Harris, D. E.; Quail, M. A.; Kieser, H.; Harper, D.; Bateman, A.; Brown, S.; 
Chandra, G.; Chen, C. W.; Collins, M.; Cronin, A.; Fraser, A.; Goble, A.; Hidalgo, J.; Hornsby, 
T.; Howarth, S.; Huang, C. H.; Kieser, T.; Larke, L.; Murphy, L.; Oliver, K.; O'Neil, S.; 
Rabbinowitsch, E.; Rajandream, M. A.; Rutherford, K.; Rutter, S.; Seeger, K.; Saunders, D.; 
Sharp, S.; Squares, R.; Squares, S.; Taylor, K.; Warren, T.; Wietzorrek, A.; Woodward, J.; 
Barrell, B. G.; Parkhill, J.; Hopwood, D. A. Complete genome sequence of the model 
actinomycete Streptomyces coelicolor A3(2). Nature 2002, 417, 141. 
 (8) Bachmann, B. O.; Van Lanen, S. G.; Baltz, R. H. Microbial genome mining for 
accelerated natural products discovery: is a renaissance in the making? J. Ind. Microbiol. 
Biotechnol. 2014, 41, 175. 
 (9) Walsh, C. T.; Fischbach, M. A. Natural products version 2.0: connecting genes to 
molecules. J. Am. Chem. Soc. 2010, 132, 2469. 
 (10) Cox, C. L.; Doroghazi, J. R.; Mitchell, D. A. The genomic landscape of ribosomal 
peptides containing thiazole and oxazole heterocycles. BMC Genomics 2015, 16, 778. 
 (11) Zhang, Q.; Doroghazi, J. R.; Zhao, X.; Walker, M. C.; van der Donk, W. A. 
Expanded natural product diversity revealed by analysis of lanthipeptide-like gene clusters in 
actinobacteria. Appl. Environ. Microbiol. 2015, 81, 4339. 
 (12) Fischbach, M. A.; Walsh, C. T. Assembly-line enzymology for polyketide and 
nonribosomal peptide antibiotics: logic, machinery, and mechanisms. Chem. Rev. 2006, 106, 
3468. 
 (13) Wang, H.; Fewer, D. P.; Holm, L.; Rouhiainen, L.; Sivonen, K. Atlas of 
nonribosomal peptide and polyketide biosynthetic pathways reveals common occurrence of 
nonmodular enzymes. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 9259. 
 (14) Yamada, Y.; Kuzuyama, T.; Komatsu, M.; Shin-Ya, K.; Omura, S.; Cane, D. E.; 
Ikeda, H. Terpene synthases are widely distributed in bacteria. Proc. Natl. Acad. Sci. U. S. A. 
2015, 112, 857. 
12 
 
 (15) Medema, M. H.; Blin, K.; Cimermancic, P.; de Jager, V.; Zakrzewski, P.; 
Fischbach, M. A.; Weber, T.; Takano, E.; Breitling, R. antiSMASH: rapid identification, 
annotation and analysis of secondary metabolite biosynthesis gene clusters in bacterial and 
fungal genome sequences. Nucleic Acids Res. 2011, 39, W339. 
 (16) Skinnider, M. A.; Dejong, C. A.; Rees, P. N.; Johnston, C. W.; Li, H.; Webster, 
A. L.; Wyatt, M. A.; Magarvey, N. A. Genomes to natural products PRediction Informatics for 
Secondary Metabolomes (PRISM). Nucleic Acids Res. 2015, 43, 9645. 
 (17) Skinnider, M. A.; Johnston, C. W.; Edgar, R. E.; Dejong, C. A.; Merwin, N. J.; 
Rees, P. N.; Magarvey, N. A. Genomic charting of ribosomally synthesized natural product 
chemical space facilitates targeted mining. Proc. Natl. Acad. Sci. U. S. A. 2016, 113, E6343. 
 (18) Tietz, J. I.; Schwalen, C. J.; Patel, P. S.; Maxson, T.; Blair, P. M.; Tai, H. C.; 
Zakai, U. I.; Mitchell, D. A. A new genome-mining tool redefines the lasso peptide biosynthetic 
landscape. Nat. Chem. Biol. 2017, 13, 470. 
 (19) Corre, C.; Challis, G. L. New natural product biosynthetic chemistry discovered 
by genome mining. Nat. Prod. Rep. 2009, 26, 977. 
 (20) Dunbar, K. L.; Mitchell, D. A. Revealing nature's synthetic potential through the 
study of ribosomal natural product biosynthesis. ACS Chem. Biol. 2013, 8, 473. 
 (21) Bauerle, M. R.; Schwalm, E. L.; Booker, S. J. Mechanistic diversity of radical S-
adenosylmethionine (SAM)-dependent methylation. J. Biol. Chem. 2015, 290, 3995. 
 (22) Pierre, S.; Guillot, A.; Benjdia, A.; Sandstrom, C.; Langella, P.; Berteau, O. 
Thiostrepton tryptophan methyltransferase expands the chemistry of radical SAM enzymes. Nat. 
Chem. Biol. 2012, 8, 957. 
 (23) Zha, L.; Jiang, Y.; Henke, M. T.; Wilson, M. R.; Wang, J. X.; Kelleher, N. L.; 
Balskus, E. P. Colibactin assembly line enzymes use S-adenosylmethionine to build a 
cyclopropane ring. Nat. Chem. Biol. 2017, 13, 1063. 
 (24) Ohashi, M.; Liu, F.; Hai, Y.; Chen, M.; Tang, M. C.; Yang, Z.; Sato, M.; 
Watanabe, K.; Houk, K. N.; Tang, Y. SAM-dependent enzyme-catalysed pericyclic reactions in 
natural product biosynthesis. Nature 2017, 549, 502. 
 (25) Peck, S. C.; van der Donk, W. A. Phosphonate biosynthesis and catabolism: a 
treasure trove of unusual enzymology. Curr. Opin. Chem. Biol. 2013, 17, 580. 
13 
 
 (26) Horsman, G. P.; Zechel, D. L. Phosphonate biochemistry. Chem. Rev. 2017, 117, 
5704. 
 (27) Hendlin, D.; Stapley, E. O.; Jackson, M.; Wallick, H.; Miller, A. K.; Wolf, F. J.; 
Miller, T. W.; Chaiet, L.; Kahan, F. M.; Foltz, E. L.; Woodruff, H. B.; Mata, J. M.; Hernandez, 
S.; Mochales, S. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science 
1969, 166, 122. 
 (28) Michalopoulos, A. S.; Livaditis, I. G.; Gougoutas, V. The revival of fosfomycin. 
Int. J. Infect. Dis. 2011, 15, e732. 
 (29) Metcalf, W. W.; van der Donk, W. A. Biosynthesis of phosphonic and phosphinic 
acid natural products. Annu. Rev. Biochem. 2009, 78, 65. 
 (30) Diddens, H.; Dorgerloh, M.; Zahner, H. Metabolic products of microorganisms. 
176. On the transport of small peptide antibiotics in bacteria. J. Antibiot. 1979, 32, 87. 
 (31) Circello, B. T.; Miller, C. G.; Lee, J. H.; van der Donk, W. A.; Metcalf, W. W. 
The antibiotic dehydrophos is converted to a toxic pyruvate analog by peptide bond cleavage in 
Salmonella enterica. Antimicrob. Agents Chemother. 2011, 55, 3357. 
 (32) Horiguchi, M.; Kandatsu, M. Isolation of 2-aminoethane phosphonic acid from 
rumen protozoa. Nature 1959, 184, 901. 
 (33) Repeta, D. J.; Ferron, S.; Sosa, O. A.; Johnson, C. G.; Repeta, L. D.; Acker, M.; 
DeLong, E. F.; Karl, D. M. Marine methane paradox explained by bacterial degradation of 
dissolved organic matter. Nat. Geosci. 2016, 9, 884. 
 (34) Young, C. L.; Ingall, E. D. Marine dissolved organic phosphorus composition: 
insights from samples recovered using combined electrodialysis/reverse osmosis. Aquat. 
Geochem. 2010, 16, 563. 
 (35) Yu, X.; Doroghazi, J. R.; Janga, S. C.; Zhang, J. K.; Circello, B.; Griffin, B. M.; 
Labeda, D. P.; Metcalf, W. W. Diversity and abundance of phosphonate biosynthetic genes in 
nature. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 20759. 
 (36) Liu, S.; Lu, Z.; Jia, Y.; Dunaway-Mariano, D.; Herzberg, O. Dissociative 
phosphoryl transfer in PEP mutase catalysis: structure of the enzyme/sulfopyruvate complex and 
kinetic properties of mutants. Biochemistry 2002, 41, 10270. 
14 
 
 (37) Seidel, H. M.; Freeman, S.; Seto, H.; Knowles, J. R. Phosphonate biosynthesis: 
isolation of the enzyme responsible for the formation of a carbon-phosphorus bond. Nature 1988, 
335, 457. 
 (38) Bowman, E.; McQueney, M.; Barry, R. J.; Dunaway-Mariano, D. Catalysis and 
thermodynamics of the phosphoenolpyruvate/phosphonopyruvate rearrangement. Entry into the 
phosphonate class of naturally occurring organophosphorus compounds. J. Am. Chem. Soc. 
1988, 110, 5575. 
 (39) Blodgett, J. A.; Thomas, P. M.; Li, G.; Velasquez, J. E.; van der Donk, W. A.; 
Kelleher, N. L.; Metcalf, W. W. Unusual transformations in the biosynthesis of the antibiotic 
phosphinothricin tripeptide. Nat. Chem. Biol. 2007, 3, 480. 
 (40) Cicchillo, R. M.; Zhang, H.; Blodgett, J. A.; Whitteck, J. T.; Li, G.; Nair, S. K.; 
van der Donk, W. A.; Metcalf, W. W. An unusual carbon-carbon bond cleavage reaction during 
phosphinothricin biosynthesis. Nature 2009, 459, 871. 
 (41) Ju, K. S.; Gao, J.; Doroghazi, J. R.; Wang, K. K.; Thibodeaux, C. J.; Li, S.; 
Metzger, E.; Fudala, J.; Su, J.; Zhang, J. K.; Lee, J.; Cioni, J. P.; Evans, B. S.; Hirota, R.; 
Labeda, D. P.; van der Donk, W. A.; Metcalf, W. W. Discovery of phosphonic acid natural 
products by mining the genomes of 10,000 actinomycetes. Proc. Natl. Acad. Sci. U. S. A. 2015, 
112, 12175. 
 (42) Circello, B. T.; Eliot, A. C.; Lee, J. H.; van der Donk, W. A.; Metcalf, W. W. 
Molecular cloning and heterologous expression of the dehydrophos biosynthetic gene cluster. 
Chem. Biol. 2010, 17, 402. 
 (43) Borisova, S. A.; Circello, B. T.; Zhang, J. K.; van der Donk, W. A.; Metcalf, W. 
W. Biosynthesis of rhizocticins, antifungal phosphonate oligopeptides produced by Bacillus 
subtilis ATCC6633. Chem. Biol. 2010, 17, 28. 
 (44) Kim, S. Y.; Ju, K. S.; Metcalf, W. W.; Evans, B. S.; Kuzuyama, T.; van der Donk, 
W. A. Different biosynthetic pathways to fosfomycin in Pseudomonas syringae and 
Streptomyces species. Antimicrob. Agents Chemother. 2012, 56, 4175. 
 (45) Woodyer, R. D.; Shao, Z.; Thomas, P. M.; Kelleher, N. L.; Blodgett, J. A.; 
Metcalf, W. W.; van der Donk, W. A.; Zhao, H. Heterologous production of fosfomycin and 
identification of the minimal biosynthetic gene cluster. Chem. Biol. 2006, 13, 1171. 
15 
 
 (46) Woodyer, R. D.; Li, G.; Zhao, H.; van der Donk, W. A. New insight into the 
mechanism of methyl transfer during the biosynthesis of fosfomycin. Chem. Commun. 2007, 
359. 
 (47) Whitteck, J. T.; Malova, P.; Peck, S. C.; Cicchillo, R. M.; Hammerschmidt, F.; 
van der Donk, W. A. On the stereochemistry of 2-hydroxyethylphosphonate dioxygenase. J. Am. 
Chem. Soc. 2011, 133, 4236. 
 (48) Cooke, H. A.; Peck, S. C.; Evans, B. S.; van der Donk, W. A. Mechanistic 
investigation of methylphosphonate synthase, a non-heme iron-dependent oxygenase. J. Am. 
Chem. Soc. 2012, 134, 15660. 
 (49) Peck, S. C.; Chekan, J. R.; Ulrich, E. C.; Nair, S. K.; van der Donk, W. A. A 
common late-stage intermediate in catalysis by 2-hydroxyethyl-phosphonate dioxygenase and 
methylphosphonate synthase. J. Am. Chem. Soc. 2015, 137, 3217. 
 (50) Bougioukou, D. J.; Mukherjee, S.; van der Donk, W. A. Revisiting the 
biosynthesis of dehydrophos reveals a tRNA-dependent pathway. Proc. Natl. Acad. Sci. U. S. A. 
2013, 110, 10952. 
 (51) Moutiez, M.; Seguin, J.; Fonvielle, M.; Belin, P.; Jacques, I. B.; Favry, E.; Arthur, 
M.; Gondry, M. Specificity determinants for the two tRNA substrates of the cyclodipeptide 
synthase AlbC from Streptomyces noursei. Nucleic Acids Res. 2014, 42, 7247. 
 (52) Ortega, M. A.; Hao, Y.; Walker, M. C.; Donadio, S.; Sosio, M.; Nair, S. K.; van 
der Donk, W. A. Structure and tRNA specificity of MibB, a lantibiotic dehydratase from 








2.1.1 Methylphosphonate Synthase and 2-Hydroxyethylphosphonate Dioxygenase: Non-
Heme Iron-Dependent Oxygenases 
 Two phosphonate natural products of substantial human interest both involve an unusual 
carbon-carbon bond cleavage step in their biosynthesis. Phosphinothricin, which was originally 
discovered as a metabolite of Streptomyces viridochromogenes DSM 40736,1 is a glutamine 
synthase inhibitor used as a herbicide.2 The exopolysaccharide decoration methylphosphonate 
from the marine archaeon Nitrosopumilus maritimus SCM1 has been linked to the production of 
methane in the aerobic ocean.3 Phosphinothricin and methylphosphonate each originate from the 
primary metabolite discussed in Chapter 1, phosphoenolpyruvate, which is carried through to the 
common intermediate 2-hydroxyethylphosphonate (2-HEP, Figure 2.1). At this point, the 
pathways diverge to produce hydroxymethylphosphonate (HMP) and methylphosphonate (MPn), 
catalyzed by 2-hydroxyethylphosphonate dioxygenase (HEPD) and methylphosphonate synthase 
(MPnS), respectively.  
                                                 
* Parts of this chapter adapted and reproduced with permission from Born, D. A.; Ulrich, E. C.; Ju, K-S.; Peck, S. C.; 
van der Donk, W. A.; Drennan, C. L. Structural basis for methylphosphonate biosynthesis. Science 2017, 358, 1336-
1339. Copyright (2017) The American Association for the Advancement of Science. X-ray crystallographic studies 
were performed and analyzed by DAB and CLD. Figure 2.4 was provided by DAB. KSJ performed bioinformatic 




Figure 2.1 General biosynthetic scheme for phosphinothricin and methylphosphonate esters 
highlighting the reactions of HEPD and MPnS. 
 
HEPD and MPnS are both members of the cupin superfamily of non-heme iron-
dependent oxygenases, which is a large set of enzymes of diverse functions, with the shared 
feature of reduction of molecular oxygen.4 A common motif of this superfamily involves binding 
Fe(II) with a 2-His-1-carboxylate facial triad of active site residues, leaving three available 
positions for oxygen and substrate/cofactors to bind in multiple different arrangements, such as 
in mono- or bidentate configurations. This flexibility in coordination is distinct from the more 
rigid heme cofactor. However, notable exceptions to the canonical facial triad have been 
discovered, in addition to the already inherent diversity in reactivity. One example is the 










































allows for a chloride ion to fill the vacant coordinating position and facilitates radical rebound 
with the halogen instead of the ferric-hydroxyl. Another common feature of non-heme iron-
dependent enzymes is the use of a cofactor to provide additional electrons for the reduction of 
molecular oxygen. A large group of enzymes requires alpha-ketoglutarate, which is oxidized to 
succinate and CO2 over the course of catalysis.4  
A crystal structure of HEPD revealed that its active site contains the three canonical iron-
ligating residues His129, Glu176, and His182 that form the 2-His-1-carboxylate facial triad.7 
HEPD and MPnS only share 21% sequence identity, but His148 and His190 of MPnS were 
proposed as the iron-binding residues based on a sequence alignment with HEPD.8 However, a 
carboxylate residue did not align with HEPD-Glu176, leaving the third ligand of MPnS 
unknown. Both enzymes are part of a specialized subgroup of non-heme iron-dependent 
enzymes in that they do not require any additional cofactors or cosubstrates to provide the four 
electrons for molecular oxygen reduction.9 All of the electrons instead come from the small, 
aliphatic 2-HEP substrate. However, HEPD and MPnS have two distinct ways of oxidizing their 
substrate. Previous researchers in the van der Donk laboratory used 13C labeling of 2-HEP to 
determine that both carbons of 2-HEP are oxidized by HEPD to give HMP and formate, while 
MPnS only oxidizes at the C2 position to form CO2 and MPn (Figure 2.2).3,7 Additionally, 
deuterium labeling helped establish that the pro-S hydrogen at the C2 position is initially 
abstracted, and the pro-R hydrogen is transferred to formate in the case of HEPD reactivity and 





Figure 2.2 Labeling studies of 2-HEP with 13C and 2H. These studies have provided insight into 
the unusual reactions catalyzed by MPnS and HEPD, which require no additional source of 
electrons. 
 
2.1.2 Proposed Mechanism and Evidence for the Last Common Intermediate 
 A common mechanism for MPnS and HEPD has been proposed based on experimental 
observations of the activity of HEPD-E176A and HEPD-E176H mutants. Both mutants were 
shown to have similar steady state kinetic parameters to WT HEPD, yet HEPD-E176A 
accumulated an Fe(IV) intermediate to a greater extent than WT (allowing for spectroscopic 
characterization),11 and HEPD-E176H resulted in the production of roughly equal amounts of 
both HMP and MPn.12 This latter bifunctional enzyme provided evidence that a shared 
mechanism could exist with a branch point leading toward separate products. A proposed 
mechanism is outlined in Figure 2.3, starting with oxygen activation and initial hydrogen atom 














































Figure 2.3 Proposed common mechanism for HEPD and MPnS leading up to the formation of a 
MPn radical and formate as the last shared step. Direct hydroxylation of the ketyl radical anion 
(pink arrows) cannot be ruled out. In addition, a methylphosphonate cation that is hydroxylated 
or protonated via hydride attack cannot be ruled out as the last step. Figure adapted from Peck et 
al.11 
 
The HEPD-E176H mutant that forms both HMP and MPn in about equal amounts 
allowed for an interrogation of the last step in the mechanism with the MPn radical and formate 
intermediates.12 The proposal involves the breakage of the formate C-H bond, with the hydrogen 
originating from the pro-R position on C2 of 2-HEP. If the mechanistic hypothesis is correct, 
incubation with the pro-R deuterium-labeled 2-HEP should result in a kinetic isotope effect on 




































































barrier to abstract a deuterium from formate. When the HEPD-E176H mutant was incubated with 
the pro-S deuterium-labeled 2-HEP substrate, the ratio of HMP and MPn production did not 
change. However, when pro-R deuterium-labeled 2-HEP was used as substrate, significantly 
more HMP was produced at the expense of forming MPn, as predicted by the mechanism.12 
Moving forward with this common mechanistic proposal in hand, some outstanding questions 
are what elements of the HEPD and MPnS active sites dictate the formation of their respective 
products even when starting from the same initial mechanism? Can we identify what residues of 
each enzyme control the fate of 2-HEP? 
 
2.1.3 MPnS and the Methane Paradox 
 The ability to distinguish between a functional MPnS versus a functional HEPD would be 
of great interest to the study of methane production and global carbon/phosphorus cycles. The 
aerobic ocean is supersaturated with methane, accounting for up to 4% of the global methane 
budget.13-15 However, the ‘oceanic methane paradox’ refers to the fact that no biological source 
was known to provide an explanation for this large accumulation of methane in an aerobic 
environment.16 Professor David Karl (University of Hawaii) developed a hypothesis, stating that 
methane can originate from MPn through phosphonate breakdown using the C-P lyase pathway 
in phosphorus-starved organisms.15 His laboratory showed that methane is produced when sea 
samples are incubated with MPn added in vitro. In addition, the Giovannoni laboratory (Oregon 
State University) determined that phosphate-starved organisms of the SAR11 clade of marine 
bacteria produce methane.17 Gratifyingly, the C-P lyase degradation system is already known to 
be abundant in marine microbes,18,19 but at the time no known biosynthetic pathways led to MPn 
production. The discovery of the MPnS enzyme encoded in a gene cluster containing pepM from 
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N. maritimus linked MPn production to established phosphonate biosynthetic routes, albeit with 
an unusual carbon-carbon bond cleavage step to yield MPn.3 More recently, MPn polysaccharide 
esters were directly isolated from ocean samples as part of dissolved organic matter.20 If we can 
determine features of MPnS that would aid in the prediction of its prevalence in marine 
microbes, we could provide essential evidence to help resolve the oceanic methane paradox.  
 
2.1.4 Analysis of MPnS Homologs 
 As part of a screen for novel phosphonate compounds from Streptomyces conducted by 
the Metcalf laboratory (UIUC, discussed in Chapter 1), a number of Streptomyces species were 
found to contain gene clusters encoding enzymes related to MPnS and HEPD. The enzymes from 
S. albus NRRL B-16041, S. griseus NRRL F-5144, S. griseofuscus NRRL B-5429, and S. 
monomycini NRRL B-24309 were found to form a clade with MPnS, and thus were expected to 
produce MPn (see Figure 5.11 from Dr. Spencer Peck’s thesis).21 Dr. Spencer Peck, a previous 
graduate student in the van der Donk laboratory, determined that all of the enzymes surprisingly 
produced HMP instead, further begging the question what features of the MPnS active site are 
essential for MPn formation. This new set of enzymes that produce HMP, specifically the S. 
albus HEPD (SaHEPD), provided an even better model for comparison to MPnS, given that 
SaHEPD and MPnS share a higher sequence identity (34%) compared to the HEPD originally 
studied from S. viridochromogenes (SvHEPD, 21%). Overall, analysis of homology based on a 
phylogenetic tree could not distinguish between MPnS and HEPD activity, and therefore 
structural information was sought for MPnS and SaHEPD to determine key differences between 




2.2 RESULTS AND DISCUSSION 
2.2.1 X-ray Crystallography Reveals the Active Site Structure of MPnS and SaHEPD 
 Because the activity of MPnS and HEPD homologs could not be predicted based on 
sequence alignments, a collaboration was established with David Born and Professor Catherine 
Drennan (MIT) to gain more insight into what might distinguish each active site. David 
determined crystal structures of MPnS in both the substrate-free and the Fe(II)- and substrate-
bound states to 2.37 Å and 2.35 Å resolution, respectively. As expected based on sequence 
homology, the structure of MPnS is highly similar to the previously characterized SvHEPD with 
a root mean square deviation of 3.6 Å for alpha carbons.22 One unexpected feature of the active 
site was that MPnS has an unusual Gln residue ligating the Fe(II), forming an unprecedented 2-
His-1-Gln facial triad. The three-dimensional placement of Gln152 in MPnS is different from 
that of the iron coordinating Glu176 in SvHEPD, instead being provided by an adjacent ß-strand. 
Gln152 is therefore positioned analogously to the iron-coordinating Glu142 in 2-
hydroxypropylphosphonate epoxidase (HppE), another non-heme iron-dependent enzyme 
involved in phosphonate biosynthesis.23 After finding another exception to the 2-His-1-
carboxylate facial triad, our first hypothesis was that this Gln was critical for MPn formation. 
 Our assumption about the Gln residue turned out to be false, at least after initial 
investigation. David determined a crystal structure of SaHEPD at 1.8 Å resolution, which also 
contains a 2-His-1-Gln facial triad with residues His149, Gln153, and His190 (Figure 2.4). Since 
the presence of the 2-His-1-Gln set of ligands does not appear to distinguish HEPD or MPnS 
activity, we wondered what differences may exist between the MPnS and SaHEPD active sites. 
David determined that the SaHEPD crystal structure affords four independent views of the active 
site. Interestingly, in two of the four active sites, Gln153 is in an iron-coordinating conformation. 
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However, in the other two active sites, Gln153 can flex downward pointing away from the Fe(II) 
to occupy a pocket lined with Gly184 and Tyr163, leaving a water molecule to replace Gln153 as 
the ligand to Fe(II) (Figure 2.4). The Gly184 residue allows for the formation of a space below 
Gln153, and Tyr163 appears to hydrogen bond to Gln153 when it occupies this cavity. 
Interestingly, these two residues represent essentially the only deviation between the SaHEPD 
and MPnS active sites. In MPnS, Gly184 is replaced by Ile184, which fills the cavity and appears 
to keep Gln152 coordinated to the iron. Tyr163 is replaced by Phe162. 
 
Figure 2.4 The MPnS and SaHEPD active sites. a) An overlay of MPnS (cyan and pink) and 
SaHEPD (yellow and green). The two colors are to distinguish the separate monomers. The 2-
His-1-Gln facial triad residues are labeled (MPnS numbering first), along with the substrate 2-
HEP and the Tyr/Gly and Phe/Ile residue pairs discussed in the text. b) A view of the SaHEPD 
active site with the Gln153 ligand flexed downward into the pocket next to Gly184 and Tyr163 





2.2.2 Site-Directed Mutagenesis to Determine Active Site Elements Essential for MPnS 
Activity 
 We wondered if the Tyr163/Gly184 pair in the SaHEPD active site and the flexibility of 
the Gln153 ligand contribute to HMP product formation over MPn production. In order to test 
this, I generated the SaHEPD Y163F/G184I double mutant to convert the two residues into the 
MPnS counterparts. We hypothesized that this would limit the movement of the Gln153 and 
force it to remain coordinated to the iron. Excitingly, the activity of this mutant enzyme was 
completely switched to afford MPn as the only product as measured by 31P NMR spectroscopy 
(Figure 2.5). Even after mutation of two residues close to the active site, SaHEPD Y163F/G184I 
still maintained catalytic parameters for MPn production similar to those of the wild-type 
enzyme for HMP production (Figure 2.6). The mutant also has a slightly higher kcat than 
NmMPnS (kcat = 0.18 s-1, KM,2-HEP = 4.5 µM).8 I also tested the single mutants SaHEPD- Y163F 
and G184I and determined that changing only Gly184 is necessary to switch the enzyme activity 





Figure 2.5 31P NMR spectroscopic analysis of the reactions with SaHEPD variants and 2-HEP as 
substrate. Peak assignments were confirmed by spiking with authentic material. The chemical 
shifts of phosphonates in 31P NMR spectroscopy are very sensitive to pH near their pKa values, 





 SaHEPD SaHEPD Y163F/G184I 
KM, 2-HEP apparent (µM) 12 ± 2 15 ± 2 
KM, oxygen (µM) 61 ± 6 95 ± 15 
kcat (s-1) 1.1 ± 0.1 1.2 ± 0.1 
kcat/KM, 2-HEP 
(M-1s-1) 
(9.2  ±  1.7) x 104 (8.0  ±  1.3) x 104 
kcat/KM, oxygen 
(M-1s-1) 
(1.8  ±  0.2) x 104 (1.3  ±  0.2) x 104 
 
Figure 2.6 Steady-state Michaelis-Menten kinetic parameters of SaHEPD WT and 
Y163F/G184I. SaHEPD WT (red) and Y163F/G184I (blue) reaction rates with varying 2-HEP 
(top) and oxygen (bottom) concentrations were fit to the Michaelis-Menten equation. Error bars 
represent the standard deviation calculated from triplicate experiments.  
 
Our observations led to a proposal that the active site Gln ligand and Gly/Ile184 are 
indicators of MPn versus HMP formation. The critical point in the mechanism involves formate 
and a MPn radical poised to react (Figure 2.3). We propose that direction down a pathway 
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leading to either MPn or HMP depends on the placement of formate in the active site relative to 
the MPn radical at the final branching point in the shared mechanism. Therefore, we propose that 
the conformationally restricted Gln152 residue coordinating the iron in the active site of MPnS 
hydrogen bonds with the formate intermediate, in turn restricting the formate to a position that 
allows for hydrogen atom abstraction by the MPn radical (Figure 2.7). In contrast, the flexibility 
of the Gln153 in the SaHEPD active site removes the hydrogen bond with formate, allowing the 
formate to move away from an optimal position for radical abstraction. This movement of the 
formate primes the MPn radical to ‘rebound’ with the ferric-hydroxyl to form HMP. 
 
Figure 2.7 The proposed last common intermediates for a) MPnS and b) SaHEPD modeled in 
position as predicted based on the ability of the Gln ligand to shift positions. 
  
Our model explains how the presence of the 2-His-1-Gln facial triad does not predict 
MPn or HMP formation, but strongly suggests that the ability of the unusual Gln residue to move 
away from the iron does. Therefore, to provide more evidence for our model, I analyzed the 
activity of mutated MPnS and SaHEPD with the Gln residues converted to Ala and Glu (using 
plasmids previously prepared by Dr. Heather Cooke for MPnS). The model predicts that removal 
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of the Gln and its hydrogen bond donating capabilities with formate would allow the formate to 
migrate in a similar way as when the Gln is flexed downward. The results of site-directed 
mutagenesis targeting the Gln residues validate this prediction. Mutation in both enzymes to Ala 
results in very low activity, but ultimately HMP production. Mutation to Glu appears to have 
more of a destabilizing effect on the enzyme active sites, as the enzymes became inactive under 
the conditions tested (Figure 2.8). We note that while these results fit with our model, a number 
of reasons may account for the little to no activity of the mutant enzymes, such as deviations in 
oxygen binding to iron, oxygen activation, and/or substrate binding. 
 
Figure 2.8 31P NMR spectroscopic analysis of the reactions with enzymes mutated  
at the Gln residue. The indicated enzymes (10 µM) were incubated with 2-HEP (2 mM) as 






2.2.3 Additional Mutagenesis of the SaHEPD and MPnS Active Sites 
 As a complement to the SaHEPD Y163F/G184I double mutant, I mutated the residues of 
MPnS to the SaHEPD counterparts to make the MPnS F162Y/I184G double mutant. This 
enzyme was not as active, as 2-HEP remained after the standard reaction time of 2 h, but I found 
that the mutant is bifunctional (Figure 2.9). Now that the cavity below Gln152 has been created, 
it is possible for the Gln to disengage from coordinating the iron and formate, ultimately 
explaining the observed production of HMP. However, other factors within the architecture of 
MPnS may contribute to whether the Gln will indeed efficiently flex downward. These factors 
may contribute to the preservation of MPn formation. 
 
Figure 2.9 31P NMR spectrum of the reaction of the NmMPnS F162Y/I184G double mutant with 
2-HEP. Peak identities were confirmed by spiking with authentic standards. 
 
Finally, David found two other residues near the active site that differ between MPnS and 
SaHEPD. Residue Glu128 of MPnS is replaced with Met129 in SaHEPD, and Met182 of MPnS 
is a Val182 in SaHEPD. I generated all four single mutants to switch each residue with the 
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identity of the other. However, none of the mutant enzymes resulted in a switch in reactivity as 
was observed for the SaHEPD G184I mutant (Figure 2.10).  
 
Figure 2.10 31P NMR spectroscopic analysis of the reactions with other single SaHEPD and 
MPnS mutants. Each enzyme was provided 2-HEP as the substrate. 
 
 2.2.4 Phylogenetic Analysis of MPnS and HEPD Homologs and Expression/Activity of a 
Homolog from Pelagibacter ubique 
Going back to our model, we predicted that the presence of an Ile at position 184 
constrains the Gln ligand to coordinating to iron and hydrogen bonding to formate, thus 
positioning formate for hydrogen atom abstraction and MPn formation. To explore a larger set of 
gene products and the prevalence of an Ile aligned at that position, David Born and Dr. Kou-San 
Ju (Metcalf laboratory, UIUC, currently at The Ohio State University) performed a search of 
publicly available databases (NCBI, JGI-IMG) for homologs of MPnS, HEPD, and HppE. A 
curated list of proteins was examined for the identity of the residue aligned with position 184. Of 
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the 538 sequences, 355, or roughly 70%, contain an Ile. One of these identified proteins came 
from the genome of Pelagibacter ubique HTCC7217, a member of the SAR11 clade of aerobic 
ocean bacteria.24 The SAR11 clade is predicted to account for 1/3 of the bacteria in surface 
waters of the ocean, thus identification of a functional MPnS encoded in its genome would lend 
significant support to MPn as the source for aerobic ocean methane production discussed above. 
Therefore, we chose to express this gene product and test for activity in vitro. 
My initial attempts to express the potential MPnS from P. ubique (PuMPnS) focused on 
obtaining a His-tagged protein (plasmid prepared by Dr. Spencer Peck). However, very low 
expression yields in E. coli caused significant problems in assaying this protein. I hypothesized 
that these low yields could be attributed to the high pI (9.8) of the protein, the result of a 
sequence that is 15% Lys. In addition, the PuMPnS gene contains 33 codons considered to be 
rare for E. coli, compared to only 16 rare codons in the N. maritimus MPnS (NmMPnS) gene.25 
Therefore, I attempted expression of a codon-optimized gene cloned into pET-15 and a plasmid 
with a His10 tag at the N-terminus (pCWOri plasmid from the M. Chang/Keasling laboratories, 
UC-Berkeley, provided by Dr. Mark Walker). Unfortunately, very little pure product was 
obtained even after 8 L cultures that were used to attempt purification via Co(II) immobilized 
metal affinity chromatography. I made a last attempt with the His6-tagged construct with a leaky 
expression system, in case toxicity to E. coli had been the issue. However, very little protein was 
observed by SDS-PAGE after a trial expression. In the end, I obtained the protein as an N-
terminal MBP-tagged fusion further purified by size exclusion chromatography (plasmid 
prepared by Dr. Spencer Peck). In support of our model, MBP-PuMPnS, which contains a 2-His-
1-Gln facial triad and an Ile aligned with position 184, produced MPn in an in vitro reaction 




Figure 2.11 31P NMR spectrum of the activity assay with MBP-PuMPnS. Peak identities were 
confirmed by spiking with authentic standards. 
 
Finally, I analyzed all of the gene clusters that encode the enzymes that we biochemically 
tested for HEPD or MPnS activity for this project, and this revealed additional evidence in 
support of their in vitro function (Figure 2.12). All HEPD-containing clusters also possess a 
phpE gene, which encodes a dehydrogenase predicted to act on HMP. All MPnS-containing 
clusters are missing a phpE gene, but instead harbor putative glycosyltransferases, phospholipid 
acyltransferases, or polysaccharide biosynthesis proteins.3 PuMPnS shares 42% sequence 
identity with NmMPnS, and like the N. maritimus gene, is within a cluster that may encode 




Figure 2.12 Analysis of the genetic context of the biochemically tested HEPD/MPnS homologs 
within this project. Gene assignments are based on a BLAST® search using the NCBI 
database.26 See the methods section for full species names. 
 
2.3 SUMMARY AND OUTLOOK 
 The non-heme iron-dependent oxygenases MPnS and HEPD both catalyze the cleavage 
of an unactivated carbon-carbon bond during the biosynthesis of natural products important to 
society. The discovery of MPnS helps to explain the oceanic methane paradox, with the 
connection established between phosphonate biosynthesis and MPn, the putative source of 
aerobic ocean methane.3,15 Intriguingly, this enzyme currently found only in marine 
microorganisms carries out a different reaction but using a similar mechanism to HEPD, which 
has been found in terrestrial Streptomyces species. Further investigation of their mechanisms has 
led to an expansion of the subset of non-heme iron enzymes that do not require other cofactors 
for catalysis.9 Despite the complexity of reactions that has already been uncovered in this family 
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of enzymes, new mechanisms and biochemical transformations are still coming to light. Recent 
examples include spectroscopic evidence of a ferric species in IPNS catalysis that abstracts a 
hydrogen atom, as is also proposed in the MPnS/HEPD mechanism,27 and the discovery that 
WelO5, a halogenase, has an active site that rearranges the ferryl oxygen ligand to facilitate 
halogenation.28 Our work highlights another new active site feature, as crystallization of MPnS 
revealed a new exception found in nature to the canonical triad, with the presence of a 2-His-1-
Gln facial triad.  
 Our combined work in the areas of structural biology, biochemistry, and bioinformatics 
enabled us to examine MPnS in the context of detailed nuances in mechanism and on the oceanic 
ecosystem scale. In our collaboration with the Drennan lab, we determined that a seemingly 
insignificant difference between the MPnS and SaHEPD active sites could be used to explain 
their separate activities. The switch in activity observed upon production of SaHEPD-G184I 
forms the basis for our mechanistic proposal. For the formation of HMP, flexibility in the Gln 
ligand is necessary to allow for migration of the formate intermediate. This flexibility is achieved 
through a cavity in the active site formed by the small Gly184 of SaHEPD. The bulky Ile184 of 
MPnS prevents Gln flexibility. We further tested this hypothesis by mutating the Gln. Mutation 
to Ala to remove the Gln, and thus imitate its ability to move away from ligating to iron, resulted 
in HMP production from both SaHEPD and MPnS. 
 The results also expand our understanding of the prevalence of MPnS homologs and the 
connection to global methane production. In collaboration with Dr. Kou-San Ju, we determined 
that 70% of the MPnS/HEPD homologs currently in public databases contain the Ile184 marker 
potentially indicative of MPnS function. We confirmed that one of these homologs can produce 
MPn in vitro. Special consideration is given to this homolog, given that its producing species is 
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the abundant oceanic surface water bacterium Pelagibacter ubique HTCC7217. Additional 
biochemical validation of MPnS activity in predicted homologs will help to strengthen our 
hypothesis and expand the diversity of sequences associated with the same enzymatic activity. 
David Born identified a homolog coming from the dinoflagellate Symbiodinium microadriaticum 
CCMP 2467. Evidence of MPn production would extend this activity into proteins coming from 




Restriction enzymes (NdeI, XhoI, HindIII, DpnI), Phusion® HF polymerase, and the 
Gibson Assembly® kit were purchased from New England Biolabs (NEB). Fail Safe polymerase 
and buffers were purchased from Epicentre. Plasmids were purified using the QIAprep Spin 
Miniprep Kit (Qiagen). 
LB medium components were purchased from Fisher Scientific. Autoinduction media 
components were procured from Sigma Aldrich, Fisher Scientific, Alfa Aesar, and Acros 
Organics. Ampicillin was purchased from Fisher and GoldBio and used at a concentration of 100 
µg/mL. Chloramphenicol was obtained from Sigma Aldrich and used at a concentration of 12.5 
µg/mL. Isopropyl-β-D-thiogalactopyranoside (IPTG) was purchased from IBI Scientific. Protein 
purification buffer components HEPES, glycerol, and imidazole were obtained from Fisher 
Scientific, and KCl and maltose were purchased from Sigma Aldrich. Lysozyme from chicken 
egg white and DNase were purchased from Sigma Aldrich. Ni-NTA resin was procured from 
Qiagen. Amylose resin was purchased from New England Biolabs. PD10 desalting columns were 
obtained from GE Healthcare. 2-Hydroxyethylphosphonate (2-HEP) was prepared as described 
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previously.10 Fe(II)(NH4)2(SO4)2, Chelex® 100 sodium, and methylphosphonate were purchased 
from Sigma Aldrich. D2O was ordered from Cambridge Isotope Labs. 
 
Table 2.1 Primers for site-directed mutagenesis and the codon-optimized PuMPnS gene. 
All primers were purchased from Integrated DNA Technologies, Inc. 
Name Sequence 
SaHEPD Fw Y163F CGTCGGTCCGGTCAACTTCTACTTCCGCAGCGGTGG 
SaHEPD Rv Y163F CCACCGCTGCGGAAGTAGAAGTTGACCGGACCGACG 
SaHEPD Fw G184I GGCGACTCCGTCTGGATTCTCCCGTTCGCGCCG 
SaHEPD Rv G184I CGGCGCGAACGGGAGAATCCAGACGGAGTCGCC 
SaHEPD Fw Q153E GGCATCTCCTCTACGAGTTCACCTACTTCGTC 
SaHEPD Rv Q153E GACGAAGTAGGTGAACTCGTAGAGGAGATGCC 
SaHEPD Fw Q153A GGCATCTCCTCTACGCGTTCACCTACTTCGTC 
SaHEPD Rv Q153A GACGAAGTAGGTGAACGCGTAGAGGAGATGCC 
SaHEPD Fw V182M GAACACCGGCGACTCCATGTGGGGGCTCCCGTTCG 
SaHEPD Rv V182M CGAACGGGAGCCCCCACATGGAGTCGCCGGTGTTC 
SaHEPD Fw M129E CCGGAGTGGATCAGCGAGCTCCGCGTCGTCGAGG 
SaHEPD Rv M129E CCTCGACGACGCGGAGCTCGCTGATCCACTCCGG 
NmMPnS Fw F162Y CGGAGAAGTAAATTACTATTACAAAGATCCTG 
NmMPnS Rv F162Y CAGGATCTTTGTAATAGTAATTTACTTCTCCG 
NmMPnS Fw I184G GGTGATTCAATGTATGGTACTCCATTTACTCCTC 
NmMPnS Rv I184G GAGGAGTAAATGGAGTACCATACATTGAATCACC 
NmMPnS Fw M182V GAATACTGGTGATTCAGTGTATATTACTCCATTTACTCC 
NmMPnS Rv M182V GGAGTAAATGGAGTAATATACACTGAATCACCAGTATTC 
NmMPnS Fw E128M CCTGAATGGATTTTGATGTTATGCAAAGTTG 
NmMPnS Rv E128M CAACTTTGCATAACATCAAAATCCATTCAGG 
gBlock for PuMPnS 
codon-optimization 
Underlined/lower case = 
overhangs for cloning 
with pCWOri 



















Table 2.1 (cont.) 
  























pCWOri propagation Fw GAGAACCTGTACTTCCAAGGCATGTCTATC 

















Table 2.2 Strains and plasmids. 
 
Name Features Source 
E. coli DH5α λpir Sup E44, ∆lacU169 (ϕlacZ∆M15), 
recA1, endA1, hsdR17, thi-1, gyrA96, 
relA1, λpir phage lysogen 
29 
E. coli DH5α  NEB 
Rosetta 2 (DE3) pLysS CAMR, provides 7 rare (in E. coli) 
tRNAs for the codons CGG, AUA, 
AGG, AGA, CUA, CCC, and GGA with 




Table 2.2 (cont.) 
   
pET-15b AMPR, encodes an N terminal 6xHis-
tag® of the protein of interest, includes a 
thrombin recognition sequence 
Novagen 
pMAL-c2x AMPR, encodes an N terminal maltose 
binding protein (MBP) tag of the protein 
of interest, includes a factor Xa 
recognition sequence 
NEB 
pCWOri AMPR, TAC promoter, encodes for a N-
terminal His10 tagged protein 
Originating from the 
M. Chang/Keasling 
lab at UC-Berkeley. 
A gift from Dr. Mark 
Walker 
pET15b-SaHEPD AMPR, NdeI and XhoI restriction sites Dr. Spencer Peck 
pET15b-SaHEPD-YFGI AMPR, NdeI and XhoI restriction sites This work 
pET15b-NmMPnS AMPR, NdeI and BamHI restriction sites 3 
pET15b-NmMPnS-FYIG AMPR, NdeI and BamHI restriction sites This work 
pMALc2x-PuMPnS AMPR, EcoRI and HindIII restriction 
sites 
Dr. Spencer Peck 
pET15b-PuMPnS (natural 
gene) 
AMPR, NdeI and XhoI restriction sites Dr. Spencer Peck 
pET15b-PuMPnS (codon-
optimized gene) 
AMPR, NdeI and XhoI restriction sites 




AMPR, encodes for a N-terminal His10 
tagged protein with a TEV protease 
cleavage site, NdeI and XbaI restriction 
sites 
This work 
pET15b-NmMPnS-Q152A AMPR, NdeI and BamHI restriction sites Dr. Heather Cooke  
pET15b-NmMPnS-Q152E AMPR, NdeI and BamHI restriction sites Dr. Heather Cooke  
pET15b-SaHEPD-G184I AMPR, NdeI and XhoI restriction sites This work 
pET15b-SaHEPD-Y163F AMPR, NdeI and XhoI restriction sites This work 
pET15b-SaHEPD-Q153E AMPR, NdeI and XhoI restriction sites This work 
pET15b-SaHEPD-Q153A AMPR, NdeI and XhoI restriction sites This work 
pET15b-SaHEPD-V182M AMPR, NdeI and XhoI restriction sites This work 
pET15b-SaHEPD-M129E AMPR, NdeI and XhoI restriction sites This work 
pET15b-NmMPnS-M182V AMPR, NdeI and BamHI restriction sites This work 
pET15b-NmMPnS-E128M AMPR, NdeI and BamHI restriction sites This work 
 
2.4.2 Construction of Site-Directed Mutagenesis Plasmids 
Mutagenesis reactions were performed using the 10X reaction buffer and polymerase 
provided in the Quikchange II Site-Directed Mutagenesis Kit (Agilent). A typical reaction (50 
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µL) contained 1X Pfu buffer, 1 ng/µL of template plasmid DNA (pET15b-SaHEPD or pET15b-
NmMPnS), 0.25 µM of each primer, 0.04 mM dNTPs (Novagen), 5% v/v DMSO, and 0.05 U/µL 
Pfu Ultra HF polymerase. Samples were run through the following program on a BioRad 
thermocycler: 95 ºC 1 min, 20 cycles of 95 ºC 1 min, 60 ºC, 55 ºC, or 50 ºC 1.5 min, 72 ºC 15 
min, then 72 ºC for 5 min. Samples were then treated with DpnI and purified using the Qiagen 
PCR Purification Kit. The Quikchange product (6 µL) was used to transform chemically 
competent (NEB) or electrocompetent E. coli DH5α cells. After recovery in LB (37 ºC for 1 h), 
the culture was plated on LB/amp100 plates, and colonies were picked for plasmid preparation. 
A plasmid harboring the correct mutation was confirmed by sequencing either by ACGT, Inc. or 
the University of Illinois-Urbana Champaign Core Sequencing Facility. The entire process was 
repeated using plasmids harboring the single mutations as templates to make the double 
mutations (G184I followed by Y163F for SaHEPD and F162Y followed by I184G for 
NmMPnS). Starts on pg 266, NB 3. 
 
2.4.3 Cloning to Produce PuMPnS Constructs for Improved Expression 
A NdeI digest was set up to prepare linear pCWOri for eventual Gibson assembly®.30 
PCR was performed to amplify the linear pCWOri: 1X Buffer G (FailSafe), 0.5 µM of each 
pCWOri-propagation primer, 0.8 ng/µL of linear pCWOri straight from the digestion, and 0.03 
U/ µL of FailSafe polymerase. The following protocol was used: 98 ºC for 3 min, then 30 cycles 
of 98 ºC for 10 s, 60 ºC for 1 min, 72 ºC for 5 min, then 72 ºC for 8 min. The product was 
visualized on a 1% agarose gel, treated with DpnI, and purified using the Qiagen PCR 
Purification Kit. A gBlock designed to decrease the number of rare codons in the P. ubique gene 
for expression in E. coli was purchased from IDT to include overhangs for pCWOri and a TEV 
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protease cleavage site at the N-terminus. The gBlock was resuspended according to the 
instructions from IDT and then used directly in a Gibson assembly mix: 64 ng/µL of the gBlock 
and 3.75 ng/µL of linear pCWOri were combined with Gibson assembly mastermix (NEB) and 
incubated at 50 ºC for 1 h. An aliquot (~2 µL) was used to transform chemically competent E. 
coli DH5α cells (NEB). After recovery in SOC media (37 ºC for 1 h), the culture was plated on 
LB/amp100 plates, and colonies were picked for plasmid preparation. A plasmid harboring the 
correct sequence was confirmed by sequencing either by ACGT, Inc. or the University of 
Illinois-Urbana Champaign Core Sequencing Facility. Starts on pg 54, NB 4. 
 Subcloning was performed to insert the codon-optimized PuMPnS gene into pET15b. 
The gene was amplified from the pCWOri construct: 1X Buffer G, 0.5 µM of each primer to add 
on overhangs for pET15b, 2.5 ng/µL of the pCWOri construct as template, and 0.04 U/µL of 
Phusion polymerase (NEB). The following protocol was used: 98 ºC for 30 s, then 30 cycles of 
98 ºC for 10 s, 55 ºC for 30 s, 72 ºC for 1 min, then 72 ºC for 5 min. The sample was purified as 
described above and used in a Gibson assembly reaction: 63 ng/µL of insert with 10 ng/µL of 
vector (linear pET15b prepared as described for pCWOri) combined with mastermix as 
described above. A plasmid was prepared as described above. A mutation was later discovered in 
the stop codon. Starts on pg 84, NB 4. 
 
2.4.4 Protein Expression of SaHEPD, NmMPnS, and Variants 
E. coli Rosetta 2 (DE3) pLysS cells (Novagen) harboring the designated plasmid were 
grown in LB/amp100/cam12.5 media while shaking (200 rpm) at 37 ºC until an optical density at 
600 nm of 0.6-0.8 was reached. The culture flasks were then placed in ice water for 10 min 
before induction with IPTG (0.1 mM final concentration). The cultures were incubated for 10-12 
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h while shaking at 18 ºC. The cells were harvested by centrifugation, and the pellets were 
washed with 25 mM HEPES pH 7.5 before resuspension in 30 mL of lysis buffer (50 mM 
HEPES pH 7.5, 200 mM KCl, 20 mM imidazole, 10% (v/v) glycerol). The resuspended cells 
were treated with lysozyme (1 mg/mL) and DNase (33 U/ mL lysis buffer) and incubated at 4 ºC 
for 30 min before two passages through a chilled French pressure cell (Thermo Electron 
Corporation). The cell debris was removed by centrifugation at 35,000 × g for 1 h at 4 ºC. The 
supernatant was then incubated with equilibrated Ni-NTA resin (2.5 mL of resin per L of 
overexpression culture) for 30 min at 4 ºC before the flow-through was collected. The resin was 
washed twice with 10 column volumes of wash buffer (50 mM HEPES pH 7.5, 200 mM KCl, 50 
mM imidazole, 10% (v/v) glycerol). Protein was eluted with elution buffer (50 mM HEPES pH 
7.5, 200 mM KCl, 250 mM imidazole, 10% (v/v) glycerol), and fractions were pooled based on 
absorbance at 280 nm measured by a NanoDrop spectrophotometer (Thermo Scientific). The 
protein was concentrated to ~2 mL using an Amicon Ultra centrifugal filter with a 30 kDa 
molecular weight cut off. The protein solution was desalted using a PD10 column equilibrated 
with storage buffer (50 mM HEPES pH 7.5, 200 mM KCl, 10% (v/v) glycerol) and the eluent 
was stored at –80 ºC in aliquots. For kinetics, the protein was additionally purified by size 
exclusion chromatography (Superdex 200 preparative grade resin, GE Healthcare, on an AKTA 
FPLC). Purity was assessed by SDS-PAGE, and the concentration was measured by absorbance 
at 280 nm using a NanoDrop spectrophotometer and a theoretical extinction coefficient (M-1cm-
1) of 80,790 for SaHEPD WT, G184I, Q153E, Q153A, M129E, and V182M, 79,300 for SaHEPD 
Y163F/G184I and Y163F, 64,540 for NmMPnS WT, Q152A, Q152E, E128M, and M182V, and 
65,780 for NmMPnS F162Y/I184G (calculated using the SIB ExPASy Bioinformatics Resources 
Portal, http://www.expasy.org).31 See pg 59, NB 4. 
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2.4.5 Protein Expression of PuMPnS 
Attempts to obtain a purified His-tagged enzyme were hampered by low expression even 
after adjusting expression time and temperature (18 ºC for 4 h, 30 ºC for 2 and 4 h, and 12 ºC 
overnight) or decreasing to 50 µM IPTG for induction. In addition, an 8 L expression followed 
by Co(II) IMAC resulted in very little material. Briefly, the supernatant was prepared as 
described above (with 0.4 U DNase/ mL lysis buffer containing 10 mM imidazole), then the 
sample was filtered through a 0.45 µm filter in preparation for loading onto a 5 mL Co(II) 
cartridge (Thermo Fisher Scientific) hooked up to an AKTA FPLC. The wash buffer contained 
10 mM imidazole, and the elution buffer contained 150 mM imidazole. The sample was further 
purified by size exclusion chromatography as described above. Similarly, a codon-optimized 
gene expressed with a His6-tag resulted in almost no yield after another 8 L of expression culture 
was purified by Co(II) IMAC. A leaky expression trial was set up for this construct as well, in 
which a 100 mL expression culture of BL21 electrocompetent cells harboring pET15b with the 
codon-optimzied PuMPnS gene was grown at 30 ºC until an OD600 of ~1.5 was reached. The 
culture was then harvested and cells lysed as described above. Essentially no material was 
obtained, as judged by SDS-PAGE. As a result, a maltose binding protein-fusion was chosen for 
expression, purification, and analysis of activity. E. coli Rosetta 2 (DE3) pLysS cells (Novagen) 
harboring the designated plasmid (pMAL-c2x-PuMPnS) were grown in ZYM-5052 
autoinduction media32/amp100/cam12.5 (with tryptone substituted for N-Z amine) while shaking 
at 37 ºC until an optical density at 600 nm of 0.6-0.8 was reached. The cultures were incubated 
for 14 h while shaking at 18 ºC. The cells were harvested by centrifugation, and the pellets were 
washed with 25 mM HEPES pH 7.5 before resuspension in lysis/wash buffer (50 mM HEPES 
pH 7.5, 200 mM KCl, 10% (v/v) glycerol). The resuspended cells were treated with lysozyme (1 
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mg/mL) and DNase (33 U/mL lysis buffer) and incubated at 4 ºC for 30 min before two passages 
through a chilled French pressure cell (Thermo Electron Corporation). The cell debris was 
removed by centrifugation at 35,000 × g for 1 h at 4 ºC. The supernatant was then incubated with 
equilibrated amylose resin (1.25 mL of resin per L of overexpression culture) for 30 min at 4 ºC 
before the flow-through was collected. The resin was washed twice with 10 column volumes of 
lysis/wash buffer. Protein was eluted with elution buffer (50 mM HEPES pH 7.5, 200 mM KCl, 
10 mM maltose, 10% (v/v) glycerol), and fractions were pooled based on absorbance at 280 nm 
measured by a NanoDrop spectrophotometer (Thermo Scientific). The protein was concentrated 
to ~2 mL using an Amicon Ultra centrifugal filter with a 30 kDa molecular weight cut off. The 
protein solution was desalted using a PD10 column equilibrated with storage buffer (50 mM 
HEPES pH 7.5, 200 mM KCl, 10% (v/v) glycerol). The protein was additionally purified by size 
exclusion chromatography (Superdex 200 preparative grade resin, GE Healthcare, on an AKTA 
FPLC) and stored at –80 ºC in aliquots. Purity was assessed by SDS-PAGE, and the 
concentration was measured by absorbance at 280 nm using a NanoDrop spectrophotometer and 
a theoretical extinction coefficient (M-1cm-1) of 121,130. Starts on pg 31, final on pg 122, NB 4. 
 
2.4.6 Activity Assay by 31P NMR Spectroscopy 
NMR experiments were performed on an Agilent 600 MHz spectrometer equipped with 
an OneNMR probe. Before the general assay was performed under aerobic conditions, enzymes 
(100 µM final concentration) were reconstituted in an anaerobic chamber (Coy Laboratory 
Products) with an atmosphere of 97%/3% N2/H2 with 1 molar equivalent of Fe(II)(NH4)2(SO4)2 
in 50 mM HEPES pH 7.5 with incubation for 10 min on ice. A typical assay (500 µL) contained 
10 µM enzyme (WT or mutants) and 2 mM 2-HEP in 50 mM HEPES pH 7.5, whereas 20 µM of 
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PuMPnS was used to form additional product. After incubation for 2 h at room temperature, the 
reaction was treated with Chelex® for 20 min while shaking, and the protein was removed using 
a Millipore centrifuge filter with a 30 kDa molecular weight cut off. D2O (100 µL) was added 
(20% final v/v) before analysis by 31P NMR spectroscopy. Spectra were analyzed using 
MestReNova software version 8.0.0. See pg 174, NB 4, pg 79, 86, NB 5. 
 
2.4.7 Kinetic Characterization of SaHEPD 
Kinetic characterization was performed on a Clark-type O2 electrode (Hansatech 
Instruments). SaHEPD (WT or Y163F/G184I) was anaerobically reconstituted with varying 
amounts of Fe(II)(NH4)2(SO4)2 as described above. The amount of Fe(II) for optimal activity 
(measured by rate of oxygen consumption in air-saturated 50 mM HEPES pH 7.5 at 20 ºC with 1 
µM enzyme and 250 µM 2-HEP) was determined to be 6 molar equivalents. This value was used 
to prepare reconstituted enzyme for determination of steady-state Michaelis-Menten parameters. 
For determination of KM apparent,2-HEP, the rate of oxygen consumption was measured in air-
saturated 50 mM HEPES pH 7.5 at 20 ºC (280 µM O2) with 1 µM enzyme and varying amounts 
of 2-HEP (10-1000 µM) in a final volume of 1 mL. For determination of KM,oxygen, the rate of 
oxygen consumption was measured in 50 mM HEPES pH 7.5 at 20 ºC with varying oxygen 
content (25-525 µM, obtained by either sparging with O2 or N2 until the desired concentration 
was obtained), 1 µM enzyme, and 800 µM 2-HEP in a final volume of 1 mL. Each reaction was 
performed in triplicate. Rates were determined using the OxyGraph Plus software version 1.02, 
and data were fit to the Michaelis-Menten equation using Igor Pro version 6.32A. Starts on pg 




2.4.8 Gene Cluster Analysis 
The contig containing pepM for each species (see Table 2.3 below) was pulled from the 
NCBI database (on 2/24/16) and analyzed in Geneious version 8.1.2. Assignments were given 
based on sequence identity and e-values in a blastp search. Gene cluster diagrams were prepared 
in Clone Manager version 9. See pg 137, NB 4. 
The phosphonopyruvate decarboxylase (Ppd) was not annotated in the N. maritimus SCM1 
genome. A tblastn search using the sequence from P. ubique was used to identify the genome 
region of the likely Ppd of N. maritimus. The ORF search function in Clone Manager was used 
to identify two ORFs in this region. These genes were manually annotated into the diagram. 
 
Table 2.3 Genomic region from NCBI for putative phosphonate gene clusters. 
Species Genome Region 
Pelagibacter ubique HTCC7217 P773DRAFT scaffold 00001.1_C 
Nitrosopumilus maritimus SCM1 Complete genome 
Streptomyces albus subsp. albus strain NRRL  
B-16041 
Contig 26.1 
Streptomyces griseus subsp. griseus strain NRRL 
F-5144 
Contig 23.1 
Streptomyces monomycini strain NRRL B-24309 Genomic scaffold P063_Doro1_scaffold15 
Streptomyces griseofuscus strain NRRL B-5429 Contig 12.1 (PepM) 
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Chapter 3: Aminoacyl-tRNA-Dependent Amide Bond Formation during the 
Biosynthesis of the Phosphonopeptide Dehydrophos* 
 
3.1 INTRODUCTION 
3.1.1 Aminoacyl-tRNA-Dependent Enzymes in Natural Product Biosynthesis 
Investigations of enzyme reaction mechanisms involved in natural product biosynthesis 
continue to reveal a fascinating toolbox for the production of structural diversity.1 One example 
is nature’s ability to find new uses for aminoacyl-transfer ribonucleic acid (aa-tRNA) as a co-
substrate that can donate an amino acid for amide or ester bond formation. Considering that aa-
tRNAs have profound importance for the cell as the link between mRNA and peptide formation 
at the ribosome, it is intriguing that aa-tRNA is also accepted as a substrate for enzymes involved 
in cell wall biosynthesis, antibiotic resistance, porphyrin biosynthesis, protein degradation 
pathways, and antibiotic biosynthesis.2-6 These topics are covered in a number of comprehensive 
recent reviews.7-9 The realization that aa-tRNA is used in antibiotic biosynthesis started in 2008, 
and now aa-tRNA-dependent enzymes encoded in natural product gene clusters have been 
characterized with three different protein structural folds. These three categories are outlined 
below. 
 
                                                 
* Parts of this chapter reprinted (adapted) with permission from Ulrich, E. C. and van der Donk, W. A. Cameo 
appearances of aminoacyl-tRNA in natural product biosynthesis. Curr. Opin. Chem. Biol. 2016, 35, 29-36. 
Copyright (2016) Elsevier. https://doi.org/10.1016/j.cbpa.2016.08.018 and Ulrich, E. C.; Bougioukou, D. J.; van der 
Donk, W. A. Investigation of amide bond formation during dehydrophos biosynthesis. ACS Chem. Biol., Article 




3.1.1.1 Cyclodipeptide Synthases  
Cyclodipeptide Synthases (CDPSs; Figure 3.1), which are involved in the production of 
diketopiperazines, have structural homology with tyrosyl-tRNA synthetase (TyrRS) and TrpRS 
proteins from which they appear to have evolved.10-13 A total of 54 CDPSs have been assayed for  
 
Figure 3.1 Reactions of biochemically validated aa-tRNA-dependent enzymes.  
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activity to date, with producing organisms spread across six bacterial phyla and one eukaryotic 
species.10,11,14-19 The cyclodipeptide products formed by these proteins are comprised of 17 
different proteinogenic amino acids.15 CDPSs function through a ping-pong mechanism 
involving the sequential interaction with two aa-tRNAs at different binding sites and the initial 
formation of a covalent enzyme-amino acid intermediate at a conserved serine residue (Figure 
3.1a).10-12,20 
 
3.1.1.2 FemX and MprF Structural Homologs 
A number of other natural product biosynthetic enzymes that utilize aa-tRNA are 
structural homologs of MprF (multiple peptide resistance factor) and FemX (factors essential for 
methicillin resistance) that share the GCN5-related N-acetyltransferase (GNAT) fold. Although 
no general sequence conservation or aa-tRNA binding region has been identified, recent co-
crystal structures with substrate analogs point to common residues such as Phe and Lys involved 
in electrostatic interactions with the aa-tRNA acceptor stem region.21,22 The cell wall 
biosynthesis enzyme FemX from Weissella viridescens catalyzes the formation of branched 
peptide chains by conjugating the ε-amino group of lysine in UDP-MurNAc pentapeptide with 
L-Ala from Ala-tRNAAla (Figure 3.1c).23 Other members of the FemABX family catalyze similar 
reactions but use different aa-tRNA substrates.8 The MprF proteins catalyze the transfer of Ala 
and Lys from aa-tRNA to phosphatidylglycerol in the cell membrane to neutralize the negative 
charge of the phospholipid bilayer and decrease the permeability of positively charged 
antimicrobial peptides (Figure 3.1b).24 The next few paragraphs will highlight homologs of 
FemX and MprF in natural product biosynthesis. 
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The use of aa-tRNA in antibiotic biosynthesis was first noted for the production of 
valanimycin by Streptomyces viridifaciens MG456-hF10 (Figure 3.1d).5 The valanimycin gene 
cluster surprisingly contains an extra copy of SerRS (VlmL) in addition to the SerRS used for 
protein synthesis.25 This discovery prompted the search for an enzyme in the valanimycin 
biosynthetic pathway that would accept Ser-tRNASer as a substrate. VlmA was proposed as the 
candidate enzyme to accept aa-tRNA due to its weak homology with MprF. Based on previous 
knowledge of the valanimycin pathway, VlmA activity was reconstituted in vitro and shown to 
attach L-Ser to isobutylhydroxylamine (Figure 3.1d). 
Pacidamycins are nucleoside antibiotics with a uridyl moiety and a tetra- or pentapeptide 
chain containing a diaminobutyric acid link (Figure 3.1e).26 The gene cluster from Streptomyces 
coeruleorubidus NRRL 18370 revealed an NRPS scaffold that is responsible for production of a 
uridyl tetrapeptide, but an extra enzyme is required to add Ala.26 PacB shares 11% sequence 
identity with FemX and uses Ala–tRNAAla for peptide bond formation. Although PacB uses an 
alternative mechanism to the NRPS machinery, it still requires a substrate that is tethered to the 
pantetheinyl arm of the peptidyl carrier protein PacH.  
Another example of a compound in which nature has utilized a variety of different 
strategies to assemble a natural product is fosfazinomycin. Its gene cluster contains an ATP-
grasp enzyme, a FemX homolog, and a glutamine synthetase that are thought to form the 
amide/hydrazide linkages.27 Only the activity of the FemX enzyme is currently established and it 
adds the N-terminal Val in a Val-tRNAVal-dependent process (Figure 3.1f).28 
Finally, the biosynthetic pathway of streptothricins, such as the pathway in Streptomyces 
rochei NBRC12908 (among others), includes NRPS modules to make a linkage between an 
amino sugar and β-lysine.29 However, a gene cluster in Streptomyces luteocolor NBRC13826 
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that encodes the biosynthesis of the analog BD-12 does not contain NRPS machinery.30 Instead, 
structural homology searches identified Orf 11 as a homolog of FemX that is responsible for the 
addition of Gly to the BD-12 structure (Figure 3.1g). 
 
3.1.1.3 Lantibiotic Dehydratases 
Surprisingly, aa-tRNA was also discovered to be a substrate for enzymes involved in the 
post-translational modification of several RiPPs (ribosomally synthesized and post-
translationally modified peptides).31 These enzymes only transiently attach amino acids to their 
substrates in an aa-tRNA-dependent fashion, and the amino acids do not end up in the final 
compounds. The first discovery of these enzymes was during investigations of the lantibiotic 
nisin, which contains dehydroalanine and dehydrobutyrine residues resulting from the NisB-
catalyzed dehydration of serines and threonines, respectively, in the peptide NisA (Figure 3.2). 
NisB is a family member of the lanthionine biosynthesis enzymes (LanB), which show no 
overall homology to other protein domains and hence unlike the FemX homologs were not 
anticipated to use aa-tRNA.31 In order to activate the side chains of Ser and Thr for the 
dehydration reaction, the residues are glutamylated by a transesterification reaction with Glu-
tRNAGlu.31,32 The N-terminal domain of NisB is responsible for this glutamylation reaction, while 
the C-terminal domain is involved in subsequent Glu elimination to form the dehydrated residue. 
NisB can accept Glu-tRNAGlu from both E. coli and the native producer Lactococcus lactis.31 
Attempts to produce lantibiotics in heterologous hosts such as E. coli have provided 
insights into tRNA recognition. Unlike NisB, the dehydratase MibB involved in the biosynthesis 
of microbisporicin A1 (Figure 3.2) does not accept Glu-tRNAGlu from E. coli.33 When MibB was 
incubated with the Microbispora isoacceptor tRNAGluCUC and its corresponding GluRS, all seven 
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expected dehydrations of the substrate peptide MibA were observed. Comparison of the 
Microbispora tRNAGluCUC substrate with E. coli tRNAGlu suggested that the acceptor stem 
sequence might be important for recognition by MibB. Mutagenesis experiments and subsequent 
activity with MibB supports the recognition of the discriminator base (A73, Figure 3.2) and the 
preceding base of the acceptor stem (U72). Hence in at least two different phyla (Firmicutes for 
nisin and Actinobacteria for microbisporicin), Glu-tRNAGlu is required for dehydration.  
 
Figure 3.2 General mechanism of lantibiotic dehydratase LanB and structures of two lantibiotics 
produced in this manner. The Glu elimination reaction is shown as a concerted process but could 
involve an enolate intermediate. After dehydration, other enzymes carry out additional post-
translational modifications that result in the structures shown at the bottom. The inset shows the 




3.1.2 Updating the Biosynthetic Proposal for Dehydrophos to Include aa-tRNA 
As discussed in Chapter 1, dehydrophos is produced from PEP following common 
biosynthetic steps through the intermediate 2-HEP. A number of details have been filled in to 
complete the pathway, one of which was the characterization of the first aa-tRNA-dependent 
enzyme in phosphonate biosynthesis (Figure 3.3). The tripeptide antibiotic dehydrophos 
produced by Streptomyces luridus requires the use of two aa-tRNA-dependent enzymes for its 
biosynthesis. Dr. Despina Bougioukou, a former post-doctoral researcher in the van der Donk 
laboratory, proposed an updated pathway and determined that the C-terminal domain of DhpH 
(DhpH-C) and DhpK catalyze amide bond formation using Leu-tRNALeu and Gly-tRNAGly, 
respectively (Figure 3.3).34 The enzymes share only 16% sequence identity, yet both are 
structural homologs of FemX family members, which was key to their functional assignment.35 
DhpH-C was shown to act on (R)-(−)-1-aminoethylphosphonic acid, a phosphonate derivative of 
Ala (L-AlaP), to make a dipeptide (L-Leu-L-AlaP), with DhpK adding Gly to make the final 
tripeptide.34 
 
Figure 3.3 Proposed biosynthetic pathway to dehydrophos. DHEP: dihydroxyethylphosphonate, 







































































DhpH-C is fused to a PLP-dependent N-terminal domain, which is proposed to act before DhpH-
C in the production of the intermediate acetylphosphonate (Figure 3.3). Another PLP-dependent 
enzyme, DhpD, is proposed to function in between to perform the transamination from 
acetylphosphonate to L-AlaP.34 The use of L-AlaP as a pathway intermediate is somewhat 
surprising, as this compound itself has antibacterial properties by inhibition of alanine 
racemase.36 The coupling of L-AlaP to L-Leu by DhpH-C perhaps serves as a protection strategy 
in the middle of the pathway, or incorporation in a tripeptide may facilitate uptake by target 
organisms. 
The goal of this project was to investigate the substrate scope and specificity of DhpH-C 
to determine how this enzyme interacts with aa-tRNA compared with other natural product 
biosynthetic enzymes. This information has two main implications in terms of phosphonate 
natural products and biosynthetic gene clusters in general. Phosphonopeptides, as discussed in 
Chapter 1, commonly function as ‘Trojan horse’ antibiotics, with the proteinogenic amino acids 
playing an important role in cellular uptake.  Thus, the function of DhpH-C is linked to the 
antibacterial potential of dehydrophos. Understanding the reactivity scope of this enzyme could 
aid in the design of phosphonopeptide derivatives with altered function. Additionally, the study 
of DhpH-C contributes to a mechanistic understanding of a growing family of ligases for natural 
product structural diversity. FemX homologs have already been characterized from four 
disparate biosynthetic gene clusters, indicating the potential of this protein family to function on 
an even wider array of molecular scaffolds. Further characterization of this enzyme family will 
strengthen our dictionary of biosynthetic enzyme chemistry for decoding novel gene clusters and 




3.2 RESULTS AND DISCUSSION 
3.2.1 Site-Directed Mutagenesis of the Putative DhpH-C Active Site 
I first investigated which residues of DhpH-C may play a role in enzyme activity. With 
the help of Dr. Despina Bougioukou, analysis of a recent structure of FemX from Weissella 
viridicens co-crystallized with the last three nucleotides of the tRNAAla acceptor stem (Figure 
3.4a)21 and an I-TASSER37 model of DhpH-C facilitated choosing residues of potential 
importance within the putative DhpH-C active site (Figure 3.4b). Furthermore, previous work on 
AlbC, a CDPS involved in the production of albonoursin, revealed an Arg-rich basic patch 
suitable for interacting with the negatively charged phosphate groups of aa-tRNA.20 Thus, Arg 
residues inside the potential aa-tRNA binding pocket of DhpH-C were identified, and site-
directed mutagenesis to Ala was performed to determine the contribution of each residue to 
product formation.  
Attempts were made to establish kinetic parameters for DhpH-C and mutant enzymes as 
a means to learn more about the involvement of each residue in the mechanism. A coupled 
enzyme assay designed by Lloyd et al.38 was used to connect continuous consumption of NADH 
with turnover of L-AlaP. The assay takes advantage of producing aa-tRNA in situ and the 
formation of AMP in this process. AMP is then taken up by adenylate kinase, with the resulting 
ADP product used in conjunction with PEP and pyruvate kinase to form pyruvate. Lactate 
dehydrogenase then converts pyruvate to lactate with the oxidation of NADH, which can be 
monitored by the decrease in absorbance at 340 nm (Figure 3.5a). Total E. coli tRNA and 
varying concentrations of L-AlaP were used. DhpH-C wild-type showed Michaelis-Menten 




Figure 3.4 The DhpH-C model structure in comparison to FemX with residues chosen for 
mutagenesis. a) Crystal structure of FemX with an aa-tRNA mimic (PDB 4II9).21 b) Overlay of 
FemX with an I-TASSER model of DhpH-C (cyan) highlighting the residues of DhpH-C chosen 
for site-directed mutagenesis.  
 
is itself an inhibitor of alanine racemase, we would not expect L-AlaP to accumulate in the cell in 
the millimolar range. I investigated if an element could be added to the in vitro assay to change 
the rate. However, additions to the assay, including use of the full-length DhpH enzyme and 
inclusion of the L-AlaP producer DhpD (up to 10 µM, in case an enzyme complex is needed for 
improved activity) did not have a large effect on the concentration dependence of L-AlaP. 
Another possibility is that we did not have the correct substrate. Other phosphonate biosynthetic 
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pathways contain cytidylylated intermediates, with one of the proteins encoded in the associated 
clusters found to house a cytidylylation domain.39,40 The eleven biosynthetic enzymes of the 
dehydrophos cluster were analyzed via a BLAST® search41 for a predicted cytidylylation 
domain, however one was not found. At this time, no further predictions of an alternative 
substrate were pursued. The assay conditions without any additions were used to determine the 
catalytic efficiency of DhpH-C-F328L and R233A, but it took upwards of 100 mM L-AlaP to 
reach saturating levels (Figure 3.5c). In the end, attempts to determine Michaelis-Menten 
parameters for DhpH-C were not continued due to our doubts about the physiological relevance 
of the data. 
Instead of complete determination of Michaelis-Menten parameters, I used a qualitative 
approach to monitor product formation over time with 31P NMR spectroscopy for DhpH-C-WT 
and its mutants. Each variant was tested in a coupled enzyme assay using E. coli LeuRS to 
generate aa-tRNA in situ from E. coli total tRNA, L-Leu, and ATP. Assays were initiated with L-
AlaP and spectra were recorded every 4 min for 6 h (Figure 3.6a). All Ala mutations negatively 
impacted product formation, with the most pronounced decline resulting from mutated residues 
Arg233 and Arg290, located in a helix and loop region lining the bottom of the putative active 
site, respectively (Figure 3.6). These results imply that the use of Arg residues to bind aa-tRNA 
may be a shared feature of aa-tRNA-dependent enzymes regardless of protein structural fold, 
considering that CDPS AlbC is not related by sequence or structure to DhpH-C and other FemX-





Variant kcat (s-1) KM,L-AlaP (mM) kcat/KM (M-1s-1) 
WT 1.56 ± 0.03 6.6 ± 0.4 (2.4 ± 0.2) x 102 
R233A N/A N/A 10.7 ± 0.2 
F328L N/A N/A 2.0 ± 0.1 
 
Figure 3.5 Attempts at steady-state Michaelis-Menten kinetics for DhpH-C. a) Scheme of the 
coupled enzyme assay to measure continuous NADH consumption and ultimately steady-state 
kinetics of DhpH-C with respect to L-AlaP. Figure adapted from Bougioukou et al.34 b) Attempt 
at monitoring steady-state kinetics of DhpH-C WT. Experiments were performed in duplicate. c) 




Figure 3.6 Percent product formed in assays with DhpH-C variants. a) Percent product formed 
plotted against time of the DhpH-C reaction for Arg variants and other variants in the vicinity of 
the Lys329 residue as measured by 31P NMR spectroscopy. b) Product formation after quenching 
the reaction after 3 h for DhpH-C and variants. Experiments were performed in duplicate. 
 
Next, I examined the consequences of mutating three residues of DhpH-C that 
structurally align with three residues important for FemX activity. In the I-TASSER model, 
Arg233 is structurally in a similar location as Arg205 in the crystal structure of FemX, which is 
proposed to be important for hydrogen bonding to the phosphate group of the final nucleotide at 
the 3’ end of the tRNA acceptor stem.21 As discussed above, the R233A mutant had a 
pronounced negative effect on product formation over time. Residues Phe328 and Lys329 are 
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structurally similar to Phe304 and Lys305 of FemX, possibly forming the Phe-Lys motif for 
tRNA interaction also seen in MprF.22 The Phe residue possibly interacts with the C75 ribose of 
the tRNA acceptor stem.21 The DhpH-C-F328L mutant was still functional, however product 
formation was drastically lowered compared to wild type (Figure 3.6). Despina and I also 
removed positive charge with a K329M mutant, or displaced the positive charge with a K329R 
mutant. Both DhpH-C-K329M and K329R showed no observable activity after 12 h, indicating 
that the placement of the charge on Lys329 is critical for enzyme function (Figure 3.7).  
 
Figure 3.7 31P NMR spectroscopic analysis of the activity of DhpH-C and Lys329 variants. 
Reactions were performed with a) DhpH-C WT, b) K329R, and c) K329M. Each assay 
contained 30 µM enzyme, 5 mM L-AlaP, 6 mM L-Leu, 6 mM ATP, and 8 µM LeuRS. 
 
The analogous Phe and Lys residues of MprF and FemX were also mutated in previous 
studies, revealing almost complete inactivation.21,22 In MprF, Phe839 was mutated to Ala and 
Leu, with the Leu mutation still displaying residual activity.22 Lys840 was mutated to Ser and 
Gln, resulting in loss of activity. Phe304 of FemX was also mutated to Ala and Leu, with both 
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mutated enzymes showing activity below 10% conversion to product.21 Lys305 was mutated to 
Ala, Met, and Arg. All mutants showed less than 1% turnover to product.21 Our results with 
DhpH-C corroborate the importance of these residues, although close to 25% of activity was 
salvaged upon mutation of Phe328 to Leu. Perhaps another residue coming from the same helix 
can compensate for the missing aromatic ring for interaction with the C75 ribose of the acceptor 
stem, or this particular interaction may not be as critical for recognition of the aa-tRNA substrate 
in DhpH-C. These three sets of Phe-Lys residues targeted for mutagenesis in DhpH-C, FemX, 
and MprF align upon analysis with all of the biochemically validated antibiotic aa-tRNA-
dependent enzymes in a PROMALS server alignment (Figure 3.8). The PROMALS server takes 
both sequence and structural information into account.42 The Lys residue appears to be  
 
Figure 3.8 An alignment of aa-tRNA-dependent enzymes in antibiotic biosynthesis homologous 
to FemX or MprF. A fragment of a PROMALS42 alignment is shown highlighting the alpha443 
helix region containing the Phe and Lys residues targeted for mutagenesis (further highlighted in 
gray). Red residues are predicted to form a helical structure, while blue residues are predicted to 
form beta-sheets. 
 
conserved for almost all of the enzymes, and Phe or another aromatic residue is moderately 
conserved in the immediately preceding position (Figure 3.8). An alignment performed 
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previously using ClustalO and manually corrected based on HHpred results shows a completely 
conserved Lys amongst FemX, PacB, VlmA, DhpH, DhpK, and Orf11.44 
Finally, we chose to investigate the effects of mutating a set of residues (Trp284, Asn325, 
and Glu326) in the vicinity of the critical Lys329 residue (Figure 3.4b). The most striking effect 
on product formation came from the W284L and N325A mutants, which provides more evidence 
that this region of DhpH-C is critical for function (Figure 3.6). These results lend support to the 
proposed pocket of DhpH-C for substrate interaction, and suggest that the importance of a 
conserved Lys residue in other aa-tRNA-dependent enzymes extends to DhpH-C. 
  
3.2.2 Activity of DhpH-C with Other aa-tRNA / aaRS Cognate Pairs 
The next goal was to determine how DhpH-C activity with Leu-tRNALeu compares with 
other hydrophobic aa-tRNA cognate pairs carrying Val, Ile, and Phe. Each amino acid and its 
corresponding aminoacyl-tRNA synthetase (aaRS) were used to substitute L-Leu and LeuRS in 
the coupled enzyme assay described above for DhpH-C activity. Dr. Despina Bougioukou 
prepared IleRS and the plasmid for PheRS and Dr. Zedu Huang prepared the plasmid for ValRS. 
When the concentration of each aaRS was doubled in each assay, the reaction rate did not 
increase, indicating that the production of aa-tRNA was not the rate-limiting step under the assay 
conditions (Figure 3.9a). Furthermore, the amount of total E. coli tRNA used, which has 
different amounts of the tRNAs for various amino acids, was normalized to produce equal 




Figure 3.9 Control experiments for DhpH-C with various synthetases. a) Reaction rate does not 
increase when doubling the aaRS concentration. Reactions were set up with 3 mg/mL total tRNA 
and 35 µM DhpH-C WT (10 µM for the LeuRS sample). Spectra were collected every 4 min for 
2 h. Reactions contained 8 µM synthetase (filled markers) or 16 µM synthetase (open markers).  
67 
 
Figure 3.9 (cont.) 
b) Determination of conditions to achieve equivalent aminoacylation levels for each synthetase. 
Aminoacylation experiments were performed with different amounts of total E. coli tRNA to 
achieve comparable amounts of aminoacylated tRNA. The final conditions identified are as 
follows: 3 mg/mL of total tRNA (LeuRS), 5.1 mg/mL (IleRS), 3.9 mg/mL (ValRS), 9.6 mg/mL 
(PheRS), and 5.4 mg/mL (LeuRS*m). The bar graph represents the average of three replicates, 
with error bars indicating the standard deviation. c) The aminoacylation reaction with various 
synthetases has gone to completion. Aminoacylation reaction aliquots were quenched after 15 
min (striped) and 30 min (solid), or 1 h (striped) and 2 h (solid) for LeuRS*m to determine if the 
reaction had gone to completion. 
 
Under these conditions, production of the dipeptide was most efficient with Leu-tRNALeu 
as the substrate. When Ile-tRNAIle, Val-tRNAVal, or Phe-tRNAPhe was used, both the rate and 
extent of product formation decreased. Interestingly, similar rates and yields were observed for 
each of these alternative substrates (Figure 3.10a). Because of the experimental set-up that 
regenerates the aa-tRNA, we cannot identify if the observed change is an effect on kcat or KM, but 
the overall strong decrease in activity is clear. To distinguish whether the effect on product 
formation was a result of the change in amino acid or the change in the tRNA sequence 
delivering the amino acid, I set up an assay with Ile-tRNALeu as a substrate. In other words, using 
the tRNA for the cognate amino acid, but with the non-cognate amino acid Ile attached. The 
mutant enzyme LeuRS-Y330A/D342A/D345A (LeuRS*m, plasmid provided by the Martinis 
laboratory, UIUC, purified by Dr. Despina Bougioukou) has been shown previously to 




Figure 3.10 DhpH-C activity with various amino acids. a) Percent product formation as 
measured by 31P NMR spectroscopy plotted against reaction time for the DhpH-C coupled 
enzyme reaction with various amino acids and their cognate aaRS/tRNA pairs. All reactions 
were conducted with total tRNA from E. coli. b) Product formation after quenching the reaction 
after 3 h for DhpH-C with various aaRSs. Experiments were performed in duplicate. 
 
When Ile-tRNALeu was the substrate for DhpH-C, similar levels of product formation were 
observed compared to the Ile-tRNAIle reaction, with both being significantly slower than the 
reaction containing Leu-tRNALeu (Figure 3.10a). Thus, at minimum the identity of the amino 
acid is important for product formation by DhpH-C. DhpH-C acceptance of other amino acids is 
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significant, despite the more gradual rate of product formation for the other dipeptides. These 
results reveal that the ligation step in the dehydrophos pathway could potentially be exploited to 
introduce structural diversity into the final natural product.  
 
3.2.3 DhpH-C Activity with Amino(phenyl)methylphosphonic Acid 
 Increased natural product structural diversity may also be possible if DhpH-C can accept 
other phosphonate peptide mimics. A phenylglycine phosphonate derivative 
(amino(phenyl)methylphosphonic acid, PhgP) was tested in place of L-AlaP with both Leu-
tRNALeu and Phe-tRNAPhe as cosubstrates. Dr. Despina Bougioukou designed these experiments 
with the idea of using DhpH-C towards the enzymatic production of the antihypertensive 
phosphonate K-26 (another phosphonopeptide, see Chapter 1 Figure 1.2). K-26 consists of L-Tyr 
and Ac-L-Ile ligated to a phosphonate derivative of L-Tyr. PhgP was chosen initially rather than 
the phosphonate analog of Tyr because it is commercially available. DhpH-C did produce a new 
peak in the 31P NMR spectrum in the sample with Leu, however very little, if any product was 
observed with Phe (Figure 3.11). It should be noted that PhgP is a racemic mixture, and only the 
S enantiomer is expected to serve as a substrate for DhpH-C. The investigation towards the 
production of K-26 was not continued further, as these results imply that the DhpH-C active site 
cannot tolerate two bulky aromatic side chains. However, this assay indicated that DhpH-C may 
be able to tolerate other phosphonate amino acid derivatives, a key finding for the possibility of 




Figure 3.11 Activity of DhpH-C with PhgP. The assays were performed with the a) Phe-
tRNAPhe or b) Leu-tRNALeu in situ production systems. Samples were incubated for 5 h before 
preparation for 31P NMR analysis. 
 
3.2.4 Mutagenesis of the tRNALeu Acceptor Stems to Test Substrate Specificity 
We have shown that DhpH-C exhibits flexibility in its substrate scope with respect to the 
proteinogenic amino acid and the phosphonate, and the final piece is its specificity with respect 
to the interaction with the tRNA. Previous work on other aa-tRNA-dependent enzymes involved 
in antibiotic biosynthesis has shown that enzyme function can be affected by changes in the 
acceptor stem bases. In particular, previous studies on the CDPS AlbC showed that the enzyme 
prefers tRNA substrates with a G1-C72 base pair match at the top of the acceptor stem.20 
Another example is the lantibiotic dehydratase MibB and its recognition of Microbispora tRNA 
as mentioned in the introduction.33 My goal was to determine if DhpH-C shares these features 
with these enzymes that are unrelated in sequence, but united in choice of cosubstrate. For this 
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series of experiments, I kept Leu as the amino acid and determined whether DhpH-C has a 
preference for select isoacceptors of E. coli tRNALeu. Isoacceptor tRNAs were obtained by in 
vitro transcription and will be named herein based on their anticodon sequence. To investigate 
whether DhpH-C recognizes changes in the first base pair at the top of the acceptor stem, the 
tRNALeu (UAG) and tRNALeu (GAG) sequences were used as substrates, since their acceptor 
stems contain a G-C match and a G-U mismatch, respectively (Figure 3.12a). We observed that 
DhpH-C does display a clear preference, since the reaction was complete with nearly 100% 
product formation in about 1 h with the tRNALeu (UAG) isoacceptor, but less than 20% product  
 
Figure 3.12 DhpH-C activity with tRNALeu mutants. a) Sequences of E. coli tRNALeu acceptor 
stems named by the sequence of their anticodon. Mutations are shown in red. b) Percent product 




was formed in 6 h with the tRNALeu (GAG) isoacceptor (Figure 3.12b). Importantly, generation 
of the tRNALeu (GAG) U72C isoacceptor mutant to introduce the G1-C72 base pair match 
resulted in the rescue of activity back to levels commensurate with the tRNALeu (UAG) substrate 
(Figure 3.12b). Such a drastic change in product formation levels with the mutation of just one 
nucleotide corroborates the hypothesis that the acceptor stem is important for recognition of the 
tRNA substrate,20,33,46 and that the anti-codon is not likely to be involved in substrate 
recognition. Interestingly, DhpH-C and AlbC are not related by structure or sequence, yet they 
have converged towards similar modes of tRNA substrate recognition.  
Finally, to probe the G1-C72 recognition element of DhpH-C further, I compared a series 
of variant tRNALeu (GAG) substrates: U72C (GC pair), G1A (AU pair), and G1A-U72C (AC 
pair). The same series of controls performed in Figure 3.9 were also done for the tRNA mutant 
reactions (Figure 3.13). FemX has been shown to require C72 for efficient product formation, 
with a G1-C72 match being most effective.46,47 For DhpH-C, none of the additional variants 
showed activity equal to the GAG (GC) substrate (Figure 3.12b). Thus, the presence of the G1-
C72 base pair match on the acceptor stem is important for DhpH-C activity. It is possible that the 
enzyme makes specific contacts with G1 and C72, or that the strong base pair helps position the 
top of the acceptor stem for enzyme interaction with the amino acid. This second possibility may 
be reminiscent of GlnRS recognition of the acceptor stem (i.e. the identity of the bases is not as 
important as a structural role they fulfill). For GlnRS, The U1-A72 base pair of tRNAGln is 
considered a recognition element,48 but not necessarily because of the identity of the nucleotides. 
Aminoacylation kinetics of tRNA mutants and a crystal structure of GlnRS with tRNAGln bound 
indicate that the tendency of the bases at positions 1 and 72 to denature is important for enzyme 
interaction over the actual identity of the bases.49,50 In summary, the experiment with DhpH-C 
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and tRNALeu mutants extends the framework of aa-tRNA-dependent enzyme recognition of 
tRNA acceptor stem elements to a FemX homolog, uniting DhpH-C with the mechanism of other 
antibiotic-producing ligases.  
The importance of the G1-C72 motif led us to reevaluate the data presented previously 
with Ile, Val, and Phe and E. coli tRNA as substrates for DhpH-C. The sequences of tRNAVal 
and tRNAPhe isoacceptors all contain a G1-C72 match (sequences obtained from the EcoCyc 
database51 for E. coli K-12 substr. MG1655), indicating that the tRNA portion of the substrate 
may still be acceptable for DhpH-C activity. Our experiment comparing Leu-tRNALeu and Ile-
tRNALeu where tRNALeu replaces tRNAIle was previously designed to account for variations in 
acceptability of the tRNA; this finding may be most critical with Ile-tRNAIle, given that tRNAIle 
isoacceptors contain either a G1-C72 or an A1-U72 match.51,52 Our reexamination of DhpH-C 
activity with various aa-tRNA cognate pairs resulted in the same conclusion that the amino acid 
portion is important for substrate recognition.  
Additionally, we can consider what we have learned from the analysis of tRNA acceptor 
stem sequences in the context of the native tRNALeu substrates for DhpH-C in Streptomyces. The 
genome of the host organism of DhpH-C, Streptomyces luridus, has not been sequenced, but the 
genome of a species that contains a similar gene cluster with a DhpH-C homolog has. Analysis 
of the tRNALeu sequences from Streptomyces sp. NRRL S-118 using the BioCyc database53 
revealed that all six isoacceptors contain a G1-C72 base pair match. Our data showing that 
DhpH-C functions best with E. coli tRNALeu with this G1-C72 match may be a feature of the 
enzyme so that it can utilize all of its native tRNALeu substrates. Other features of the host tRNA 
may exist that DhpH-C uses to distinguish between isoacceptors. One possible reason for a 
system with specific recognition requirements would be so that DhpH-C does not have to 
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compete with pathways leading to translation for Leu-tRNALeu. Other aa-tRNA-dependent 
enzymes such as the Fem proteins in Staphylococcus aureus and glutamyl-tRNA reductase 
(GluTR) recognize different tRNA elements compared to translation machinery enzyme 
elongation factor Tu (EF-Tu). In S. aureus, EF-Tu does not appear to bind strongly to three out 
of the five Gly-tRNAGly isoacceptors, potentially leaving these three available for cell wall 
biosynthesis as substrates for the Fem protein.54 A similar strategy may be at play with GluTR, 
which takes Glu-tRNAGlu for porphyrin biosynthesis. In this system, one of the three Glu-
tRNAGlu isoacceptors is not recognized by GluTR, but is recognized by EF-Tu, possibly 
safeguarding a substrate for protein synthesis.55 Future investigations of DhpH-C with 
Streptomyces tRNALeu may reveal more about its preferred substrate, possibly in relation to the 




Figure 3.13 Control experiments for DhpH-C with tRNALeu mutants. a) Reaction rate with 
various tRNALeu variants does not increase when the LeuRS concentration is doubled. Reactions 
were set up with 16 µM tRNALeu variants (8 µM for GAG (AU)) and 10 µM DhpH-C WT. 
Reactions contained 8 µM LeuRS (filled markers) or 16 µM LeuRS (open markers). b) 
Determination of conditions to achieve equivalent aminoacylation levels with each tRNALeu 
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Figure 3.13 (cont.) 
variant. Aminoacylation experiments were performed with 16 µM tRNALeu, except 8 µM was 
used for GAG (AU). The bar graph represents the average of three replicates, with error bars 
indicating the standard deviation. c) The aminoacylation reaction with tRNALeu variants has gone 
to completion. Aminoacylation experiments were performed with 16 µM tRNALeu, except 8 µM 
was used for GAG (AU). Reaction aliquots were quenched after 15 min (striped bars) and 30 
min (solid bars) to determine if the reaction had gone to completion. 
 
3.3 SUMMARY AND OUTLOOK 
 Several aa-tRNA-dependent enzymes with three distinct structural folds have been 
characterized in recent years. The CDPSs and FemX/MprF homologs were predicted to function 
with aa-tRNA based on their gene cluster context and/or their homology to previously studied 
aa-tRNA-dependent enzymes, while the LanB enzymes represent unprecedented use of the aa-
tRNA substrate. This chapter outlines efforts to characterize the enzyme-aa-tRNA interaction for 
DhpH-C and determine its similarities to other aa-tRNA-dependent enzymes. Site-directed 
mutagenesis studies revealed key residues important for enzyme function, such as a patch of Arg 
residues and a critical Lys. Upon mutation of this Lys, enzyme activity was abolished. Almost 
complete loss of enzyme function was also observed in FemX and MprF upon mutation of a Lys 
that is conserved in DhpH-C, FemX and MprF.21,22 Despite low sequence similarity, some of the 
other FemX homologs appear to share this conserved Lys, although mutagenesis studies on those 
enzymes are needed to confirm the involvement of the residue in enzyme activity. This Lys 
residue has potential in serving as a marker to determine the possible site of aa-acceptor stem 
binding in future homologs of interest. 
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Experiments with different aaRS/aa-tRNA cognate pairs established that DhpH-C does 
accept other amino acids to make a set of dipeptides. By tracking product formation over time, 
we could visualize that under our assay conditions product formation is less efficient for aa-
tRNA other than Leu-tRNALeu, even when tRNALeu is used as a substrate for another amino acid. 
The DhpH-C active site pocket appears to have a mechanism for distinguishing between amino 
acid substrates. At present, the determination that DhpH-C has flexibility in the substrates it 
accepts is a big step in considering its potential in future studies of phosphonate analog 
production.    
Finally, investigations of the tRNALeu substrate were performed with the hypothesis that 
features of the acceptor stem could be important for activity. Previous studies on enzymes of 
each structural fold family that use aa-tRNA (FemX,46 MprF,22,56 AlbC,20 and MibB33) have all 
come to the conclusion that the acceptor stem is important for enzyme recognition. Studies on 
DhpH-C support the hypothesis, as mutations in the final base pair of the acceptor stem affected 
enzyme activity. The best substrate for DhpH-C contained a G1-C72 base pair match. 
Additionally, the tRNA (GAG) isoacceptor, which is a poor substrate for DhpH-C, was 
converted into an excellent substrate through just the single U72C mutation. The sensitivity of 
enzyme activity to changes in these bases may be due to recognition of the base or due to effects 
on stability of the double stranded stem or positioning of the aa-ACC portion of aa-tRNA in the 
active site.  
Studying enzymes like DhpH-C aids in the larger goal of predicting natural product 
structure from the list of encoded enzymes in a gene cluster. An extensive effort by other groups 
to biochemically characterize over 50 CDPSs has moved the community closer to this goal for 
cyclic dipeptides. These researchers deduced a pattern in the CDPS active site residues that 
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connects to the amino acid recognized from aa-tRNA.15 They were able to confirm their 
predictions by testing 11 new CDPSs identified through genome mining. Understanding which 
amino acid is incorporated into a cyclic dipeptide product significantly helps to predict the 
scaffold of the final diketopiperazine natural product. This work begins to associate aa-tRNA-
dependent enzymes with the well-established ability to predict NRPS adenylation domain 
substrates, ultimately leading to predictions for substructures in the final natural product.57,58 
Work described in this chapter on DhpH-C strengthens our understanding of the diversity of 
reactions performed by FemX homologs and the types of residues important in their active sites. 
Only five FemX homologs encoded in antibiotic gene clusters have been characterized to date, 
making the list currently rather short for formulating reliable predictions (160 enzymes were 
examined in one study for adenylation domains).57 However, continued efforts in genome mining 
may lead to the accumulation of more gene clusters containing FemX homologs for biochemical 
analysis. Assigning the function of these enzymes in new biosynthetic pathways will advance our 




Molecular Biology: Restriction enzymes (NdeI and DpnI), Phusion® polymerase, Gibson 
Assembly® master mix, and Taq DNA ligase were purchased from New England Biolabs, Inc. 
Fail Safe PCR buffers and polymerase and T5 exonuclease were obtained from Epicentre. DTT 
was purchased from Promega. dNTPs and MgSO4 were procured from EMB Millipore. 
Ampicillin (100 µg/mL) and chloramphenicol (12.5 µg/mL) were purchased from Fisher 
Scientific and Sigma Aldrich. 
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tRNA Generation: 10X NEBufferTM 2, DNA polymerase I large Klenow fragment, rNTP 
mix, and thermostable inorganic pyrophosphatase (TIPP) were purchased from New England 
Biolabs, Inc. The dNTP mix was obtained from Novagen, Ambion® UltraPureTM BSA was 
purchased from Thermo Fisher Scientific, RNasin® RNase inhibitor and RNase-free DNase 
were purchased from Promega. 
Enzymology: Nickel-nitrilotriacetic acid agarose was obtained from Qiagen. Isopropyl-β-
D-galactopyranoside was purchased from IBI Scientific. Amicon ultracentrifugal filters were 
purchased from EMB Millipore. PD10 desalting columns were ordered from GE Healthcare. 
Chelex® 100 resin, DNase, (R)-(−)-1-aminoethylphosphonic acid (L-AlaP), PhgP, ATP, 
adenylate kinase, pyruvate kinase, and lactate dehydrogenase were purchased from Sigma 
Aldrich. L-[14C(U)]-amino acids and Ultima Gold cocktail were obtained from Perkin Elmer. 
Total tRNA from E. coli MRE 600 was purchased from Sigma Aldrich/Roche. Inorganic 
pyrophosphatase was purchased from NEB. PEP was purchased from Alfa Aesar. PDB59 and I-
TASSER37 structures were visualized using PyMOL.60  
 
Table 3.1 Primer sequences.  
All primers were purchased from Integrated DNA Technologies, Inc. 


































tRNALeu TAG Fw AATTCCTGCAGTAATACGACTCACTATAGCGGGAGTGGCGA
AATTGGTAGACGCACCA 
tRNALeu TAG Rv* mUmGGTGCGGGAGGCGAGACTTGAACTCGCACACCTTGCG
GCGCCAGAACCTAAATCTGGTGCGTCT 
tRNALeu GAG Fw AATTCCTGCAGTAATACGACTCACTATAGCCGAGGTGGTGG
AATTGGTAGACACGCTA 
tRNALeu GAG Rv* mUmGGTACCGAGGACGGGACTTGAACCCGTAAGCCCTATTG
GGCACTACCACCTCAAGGTAGCGTGTCT 












Table 3.2 Strains and plasmids. 
Name Features Source 
E. coli DH5α λpir sup E44, ∆lacU169 
(ϕlacZ∆M15), recA1,endA1, 
hsdR17, thi-1, gyrA96, relA1, 
λpir phage lysogen. 
(61) 
E. coli Rosetta 2 (DE3)pLysS CAMR; provides seven rare, in 
E. coli, tRNAs for the codons 
CGG, AUA, AGG, AGA, 
CUA, CCC, and GGA in the 
same plasmid that habors the 
T7 lysozyme 
Novagen 
pET-15b AMPR; N-terminal 6xHis-
tag® of protein, includes a 
thrombin recognition sequence 
Novagen 
pET-15b dhpH-C AMPR (NdeI/XhoI) (34) 
pET-15b dhpH-C R233A AMPR (NdeI/XhoI) This work 
pET-15b dhpH-C W284L AMPR (NdeI/XhoI) This work 
pET-15b dhpH-C R290A AMPR (NdeI/XhoI) This work 
pET-15b dhpH-C R292A AMPR (NdeI/XhoI) This work 
pET-15b dhpH-C R296A AMPR (NdeI/XhoI) This work 
pET-15b dhpH-C N325A AMPR (NdeI/XhoI) This work 
pET-15b dhpH-C E326A AMPR (NdeI/XhoI) This work 
pET-15b dhpH-C F328L AMPR (NdeI/XhoI) This work 
pET-15b dhpH-C K329M AMPR (NdeI/XhoI) This work 
pET-15b dhpH-C K329R AMPR (NdeI/XhoI) This work 




AMPR Gift from the Martinis lab 
(UIUC) (45) 
pET-15b ileRS AMPR (NdeI/XhoI) Dr. Despina Bougioukou 
pET-15b valRS* AMPR (NdeI/XhoI) (28) 
pET-15b pheRS AMPR (NdeI/XhoI) Dr. Despina Bougioukou 
* Upon sequencing pET-15b valRS, we found that it encodes the mutations I520V and Y688H 
compared to a NCBI reference sequence of valRS from DH5α (NZ_JRBB01000028.1). These 
may be the natural amino acids in the DH5α genomic DNA that we used.  
 
3.4.2 Site-Directed Mutagenesis 
For site-directed mutagenesis of DhpH-C, reactions contained 1X Pfu Ultra buffer 
(Agilent Quikchange II Mutagenesis Kit), 0.6 ng/µL of pET15b DhpH-C as template, 0.25 µM 
of each primer, 0.04 mM dNTPs (Novagen), 5% DMSO, and 0.05 U/µL Pfu Ultra HF 
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polymerase. For R290A, R296A, N325A, and E326A, the reactions contained 1X Buffer G 
(FailSafe Kit), 0.6 ng/µL of pET-15b DhpH-C, 0.5 µM of each primer, and 0.04 U/µL of 
Phusion® HF polymerase (NEB). All of these reactions were run through the following protocol: 
95 ºC for 1 min, 20 cycles of 95 ºC for 1 min, 60 ºC for 1.5 min, 72 ºC for 15 min, then 72 ºC for 
5 min. For R233A, W284L, and R292A, the mutation was introduced using Gibson cloning.63 
For example, primers DhpHC_W284L_F and pET15b_NdeI_R were used to amplify around the 
vector, while DhpHC_W284L_R and NdeI-dhpH_C353 were used to amplify the gene with 
pET-15b DhpH-C as template. The reaction contained 1X of Buffer G (FailSafe kit), 0.5 µM of 
each primer, 0.9 ng/µL template, and 0.04 U/µL Phusion® polymerase. Each fragment was 
amplified using the following touch down PCR protocol: 98 ºC for 3 min, 30 cycles of 98 ºC for 
10 s, 70 ºC for 30 s while dropping 0.5 ºC each round, 72 ºC for 8 min (vector) or 2 min (gene), 
then 72 ºC for 10 min. All samples, regardless of amplification method, were treated with DpnI 
and purified using the QIAquick PCR purification kit (Qiagen). For Gibson ligation, a 2:1 ratio 
of insert:vector was combined with assembly master mix from either NEB or prepared as 
previously described (for W284L).34 Samples incubated at 50 ºC for 1 h. For all samples, an 
aliquot (~3 µL) was used to transform 50 µL of electro-competent DH5α cells. Recovered cells 
were plated on LB/amp100 plates, which grew overnight at 37 ºC. Colonies were picked for 
plasmid preparation using the QIAprep Spin Miniprep Kit (Qiagen). Correct mutations were 
verified by sequencing either at ACGT, Inc. or the UIUC Core Sequencing Facility. Starts on pg 






3.4.3 Protein Purification 
E. coli Rosetta 2 (DE3) pLysS cells (Novagen) harboring the designated plasmid were 
grown in LB supplemented with 100 µg/mL ampicillin and 12.5 µg/mL chloramphenicol while 
shaking at 37 ºC until an optical density at 600 nm of 0.6-0.8 was reached. The culture flasks 
were then placed in ice water for 10 min before induction with IPTG (0.1 mM final 
concentration). After incubation for 10-12 h at 18 ºC while shaking, the cells were harvested by 
centrifugation, and the pellet was washed with phosphate-buffered saline buffer, pH 7.4. The 
cells were resuspended in lysis buffer (50 mM sodium phosphate pH 8.0, 300 mM NaCl, 10 mM 
imidazole, 10% glycerol), treated with 33 U DNase/mL of buffer, and incubated for 30 min at 4 
ºC. Cell lysis was performed by two passages through a chilled French pressure cell (Thermo 
Electron Corporation) and the cell debris was removed by centrifugation (35,000 × g for 1 h at 4 
ºC). The remainder of the purification procedure was performed at 4 ºC. The supernatant was 
first incubated with equilibrated Ni-NTA resin (2.5 mL resin per L overexpression culture) for 
30 min and the flow-through was collected. The resin was washed twice with 10 column 
volumes of wash buffer (50 mM sodium phosphate pH 8.0, 300 mM NaCl, 20 mM imidazole, 
10% glycerol) and the protein was eluted off the resin with elution buffer (50 mM sodium 
phosphate pH 8.0, 300 mM NaCl, 250 mM imidazole, 10% glycerol). Fractions were pooled 
based on measurement of absorbance at 280 nm on a NanoDrop spectrophotometer (Thermo 
Scientific), and the pooled fractions were concentrated to ~2 mL using an Amicon Ultra 
centrifugal filter with a 10 or 30 kDa molecular weight cut off. The concentrated fractions were 
desalted using a PD10 column equilibrated with storage buffer (50 mM sodium phosphate pH 
7.4, 10 mM KCl, 10% glycerol), and the final product was aliquoted and stored at –80 ºC. Purity 
was assessed by SDS-PAGE and the final concentration was measured by absorbance at 280 nm 
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using a NanoDrop spectrophotometer (and the Bradford assay for DhpH-C and variants). The 
theoretical extinction coefficient (M-1 cm-1) used for each protein was: 60,390 for DhpH-C and 
variants, except 54,890 for DhpH-C-W284L, 169,140 for LeuRS, 175,670 for IleRS, 170,740 for 
ValRS, 87,780 for PheRS, and 167,650 for LeuRS*m (calculated using the SIB ExPASy 
Bioinformatics Resources Portal, http://www.expasy.org).64 See pg 75, NB 2. 
 
3.4.4 Analysis of DhpH-C and Mutant Enzymes Activity by 31P NMR Spectroscopy 
NMR experiments were performed on an Agilent 600 MHz spectrometer equipped with 
an OneNMR probe. 31P NMR spectra were recorded in 20% D2O at room temperature. A typical 
reaction contained 50 mM HEPES pH 7.5, 150 mM KCl, 15 mM MgCl2, 6 mM ATP, 6 mM L-
Leu, 5 mM L-AlaP, 8 µM LeuRS, 10 µM DhpH-C WT and variants, 0.01 U/µL TIPP, and 3 
mg/mL total E. coli tRNA (Sigma Aldrich/Roche). Product formation was followed by collecting 
spectra every 4 min for 6 h. Spectra were analyzed using MestReNova version 8.0.0-10524 
software. Percent product formation was calculated by integration of peak area. Stages of the 
reactions in which less than ~10% of the product was formed or substrate remained were 
difficult to compute due to the low signal-to-noise. As a result, data for experiments that ran to 
completion were not plotted after ~85-90% product formation. Replicate endpoint assays were 
quenched by treatment with Chelex® (20 min of shaking at room temperature) and filtration 
through a 10 kDa molecular weight cut off Amicon filter (EMD Millipore). D2O (100 µL) was 
added before analysis. Results were plotted using Igor Pro version 6.32A. Starts on pg 221 NB 4. 
For DhpH-C activity with PhgP, the 500 µL reaction contained 3 mg/mL total tRNA 
from E. coli, 5 mM PhgP, 6 mM ATP, 6 mM L-Leu or L-Phe, 0.8 mg/mL LeuRS or PheRS, 1.4 
mg/mL DhpH-C, and 0.01 U/µL TIPP in 100 mM HEPES pH 7.5, 10 mM KCl, and 20 mM 
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MgCl2. The samples were incubated at room temperature for 5 h and were prepped for NMR 
analysis as described above (except 150 µL of D2O was added). See pg 6, NB 3. 
 
3.4.5 Attempts at Kinetic Characterization for DhpH-C and Select Variants 
 Experiments were performed on a Varian Cary 4000 spectrophotometer. A typical assay 
(200 µL) contained 6 mg/mL total E. coli tRNA, varying concentrations of L-AlaP, 0.025 U/µL 
of PK/LADH, 0.075 U/µL of ADK, 2 µM LeuRS, and 3 µM DhpH-C WT or variants in a buffer 
that contained 50 mM HEPES pH 7.5, 10 mM KCl, 20 mM MgCl2, 10 mM L-Leu, 250 µM ATP, 
250 µM NADH, and 2.5 mM PEP. Experiments were initiated with DhpH-C and performed in 
duplicate for each concentration of L-AlaP. The change in absorbance at 340 nm was measured 
in Hellma® Suprasil® quartz cuvettes (1 cm path length). Rates were measured using the Cary 
WinUV kinetics software version 6.0.0 1547 and data were fit to the Michaelis-Menten equation 
or a line using Igor Pro version 6.32A. See pg 193/199, NB 3. 
 
3.4.6 in vitro Transcription of tRNALeu 
Sequences for E. coli tRNALeu (UAG) and (GAG) were obtained from the EcoCyc 
database.65 dsDNA templates were prepared based on a previously described method.66 A 500 µL 
reaction for template generation contained: 1X Buffer 2 (New England Biolabs, Inc.), 4 µM of 
each primer, 40 µM of dNTPs, and 0.06 U/µL DNA polymerase I (large Klenow fragment). The 
reaction was incubated at 25 ºC for 15 min before the addition of EDTA (10 mM final 
concentration) and inactivation by heating at 75 ºC for 20 min. The DNA was precipitated in 
EtOH overnight at –20 ºC. The resulting pellet was washed three times with ice cold 75% EtOH 
and air-dried before resuspension in nuclease-free water. The entire template yield was used in 
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either a 1000 or 1500 µL in vitro transcription reaction based on a previously described 
method.67 The reaction contained 1X transcription buffer (100 mM HEPES pH 7.5, 10 mM 
MgCl2, 2 mM spermidine, 40 mM DTT, and 0.1 mg/mL RNase-free BSA), 10 mM DTT, 26 mM 
MgCl2, 7.5 mM of each NTP, 0.8 U/µL RNasin® RNase inhibitor, 0.01 U/µL TIPP, ~30 ng/µL 
template DNA, and 140 ng/µL T7 RNA polymerase. The reaction was incubated overnight at 37 
ºC, then 5 U of RNase-free DNase was added per 500 µL transcription reaction, and incubation 
continued for 1 h at 37 ºC. The reaction was desalted by filtration using a 10 kDa molecular 
weight cut-off centrifugal filter (Millipore; 4 wash cycles with 50 mM HEPES pH 7.5). The 
tRNA was purified using an acidic phenol / 24:1 chloroform:isoamyl alcohol extraction 
described previously, ending with precipitation in EtOH and resuspension in 2 mM NaOAc pH 
5.2.68 The tRNA was precipitated in EtOH overnight at –20 ºC. The resulting pellet was washed 
with ice cold 75% EtOH and air-dried before resuspension in 2 mM NaOAc pH 5.2. tRNA 
concentration was determined using a Qubit® 2.0 Fluorometer and the RNA Broad-Range assay 
kit (Thermo Fisher Scientific). See pg 212, NB 4. 
 
3.4.7 Aminoacylation of Total E. coli tRNA and in vitro Transcribed tRNA 
The reactions (15 µL) contained 37.5 mM HEPES pH 7.5, 112.5 mM KCl, 11.2 mM 
MgCl2, 5 mM ATP, 0.01 U/µL TIPP, 8 µM LeuRS, 50 µM L-[14C(U)]-Leucine (328 
mCi/mmol), and 16 µM in vitro transcribed tRNALeu (8 µM for GAG(AU)). Each solution was 
incubated at room temperature (to replicate conditions for DhpH-C activity assays) for 15 min (1 
h for LeuRS*m assays) before quenching and preparation for analysis adapted from previously 
described protocols.33,34,69,70 An aliquot of 5 µL was spotted onto 3MM Whatman filter paper 
squares presoaked in 5% trichloroacetic acid (TCA). The spots were allowed to dry for 5 min 
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before the filter paper squares were washed 3 times in cold 5% TCA and once in cold 75% EtOH 
for 5 min each. The squares were air-dried and then analyzed by liquid scintillation counting in 
Ultima Gold scintillation cocktail using a Tri-Carb 2910TR. Experiments were performed in 
triplicate. Results were plotted using Igor Pro version 6.32A. See pg 262, NB 4. 
Aminoacylation assays with total E. coli tRNA were performed as described above, 
except that 3 mg/mL tRNA was used initially before adjusting the amount of tRNA to achieve 
equivalent aminoacylation levels for each aaRS (see amounts described for the activity assay, 
Figure 3.9). In these assays, 8 µM of each aaRS was used along with the corresponding amino 
acid: L-[14C(U)]-isoleucine (308 mCi/mmol), L-[14C(U)]-valine (271 mCi/mmol), and L-
[14C(U)]-phenylalanine (477 mCi/mmol). See pg 292, NB 4. 
 
3.4.8 Analysis of DhpH-C Activity with aaRS/aa-tRNA Cognate Pairs and in vitro 
Transcribed tRNA by 31P NMR Spectroscopy 
Based on aminoacylation studies, the amount of total tRNA in each aaRS reaction was 
increased as follows: IleRS (1.7x), ValRS (1.3x), PheRS (3.2x), and LeuRS*m (1.8x). Reactions 
(same as 3.4.4) with various synthetases were incubated at room temperature with components 
needed for aminoacylation before the addition of DhpH-C WT (35 µM), with L-AlaP added to 
initiate the amide-forming reaction after 15 min (1 h for LeuRS*m). Product formation was 
monitored as described in section 3.4.4. The same reactions were set up with in vitro transcribed 
tRNALeu (16 µM or 8 µM for GAG (AU)) to monitor product formation over time (10 µM 
DhpH-C was used). Spectra were collected in the same manner except the sample with tRNALeu 
(UAG) ran for 2 h since the reaction had gone to completion within that amount of time. Starts 
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 Chapter 4: Convergent Evolution in the Biosynthesis of Fosfomycin* 
 
4.1 INTRODUCTION 
Fosfomycin (Figure 4.1) is an antibiotic approved for clinical use against urinary tract 
infections and in combination with other antibiotics against multidrug-resistant pathogens.1,2 It 
inhibits cell wall biosynthesis by covalently modifying an active site Cys residue in enolpyruvyl 
transferase MurA that attacks the epoxide.3-5 Fosfomycin is produced through different pathways 
by Gram-positive Streptomyces and Gram-negative Pseudomonas species, implying that its 
molecular structure may be an evolutionarily useful metabolite formed through convergent 
pathways. 
 
4.1.1 Convergent Evolution in Metabolite Biosynthesis 
 Fosfomycin biosynthesis stands out as a case of convergent evolution in antibiotic 
biosynthesis in that two pathways with mostly different biosynthetic enzymes that catalyze 
different reactions lead to the production of the exact same molecule. Other similar examples in 
secondary metabolite production exist, but rarely does an identical molecule emerge from the 
pathway. Gibberellin biosynthesis in plants and fungi is one such example, where different 
intermediates are formed near the end of the pathway. However, the cause of these differences is 
mainly just the timing of hydroxylations by cytochrome P450 enzymes or dioxygenases.6 
Convergence in antibiotic biosynthesis is also discussed in terms of formation of the same 
                                                 
* Parts of this chapter reprinted (adapted) with permission from Olivares, P.; Ulrich, E. C.; Chekan, J. R.; van der 
Donk, W. A.; Nair, S. K. Characterization of two late-stage enzymes involved in fosfomycin biosynthesis in 
Pseudomonads. ACS Chem. Biol. 2017, 12, 456-463. Copyright (2017) American Chemical Society. DOI: 
10.1021/acschembio.6b00939 Site-directed mutagenesis was performed by PO. X-ray crystallographic studies were 




molecular scaffold, if not the same molecule.7 Beta-lactam antibiotic biosynthesis is 
accomplished through a number of different mechanisms, with the central beta-lactam ring 
formed through adenylation or oxidation and then decoration with various ring substituents.8 
Here, different reactions are performed by unrelated enzymes for the formation of the same 
functional group, but ultimately leading to individual final molecules. In contrast, the 
biosynthesis of the exact same molecule using different enzymes and chemical strategies is seen 
in primary metabolism across the domains of life.9 An example is L-Lys biosynthesis by two 
entirely separate routes and starting materials.9 Plants and bacteria use a pathway initiated by L-
Asp that proceeds through a number of pimelate derivatives. In contrast, some eukaryotes 
produce L-Lys starting with alpha-ketoglutarate and a route involving adipate analogs. The 
pathways to fosfomycin production start and end with the same metabolites, and the next section 
will discuss proposals for how two sets of biosynthetic logic are employed to fill in the middle 
reactions. 
 
4.1.2 Fosfomycin Biosynthetic Pathway in Streptomyces and a Mechanistic Hypothesis for 
the Biosynthesis in Pseudomonas 
The complete gene cluster for fosfomycin production from Streptomyces fradiae was 
previously determined through heterologous expression and gene deletion studies in the host 
Streptomyces lividans.10 The eight genes designated fom1-4 and fomA-D were found to be 
necessary for production. The gene products FomA and FomB are both kinases responsible for 
phosphorylating fosfomycin to protect the producing species from its own antibacterial 
weapon.11 Fosfomycin biosynthesis originates from PEP and is carried forward by the common 
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decarboxylation step (see Chapter 1) to yield PnAA, which is then reduced to 2-HEP by FomC 
(Figure 4.1).12 The gene encoding for FomD was shown to be essential for fosfomycin  
 
Figure 4.1 Gene clusters and proposed biosynthetic pathways to fosfomycin from Streptomyces 
wedmorensis and Pseudomonas syringae. Steps unique to the Streptomyces pathway are in 
orange, the hypothesis for the Pseudomonas pathway is in purple, and shared steps are in black. 
The stereochemistry of phosphonomethylmalate (Pmm) has not been confirmed. 
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production, but its function was not known at the time of initial pathway construction. Fom3, a 
predicted SAM- and methylcobalamin-dependent enzyme, was also found to be part of the 
minimal gene cluster, but its substrate was unknown.10 Early attempts to reconstitute Fom3 with 
2-HEP resulted in very low turnover.13 
More recently, an additional domain on the PEP mutase Fom1 was discovered to catalyze 
cytidylylation of 2-HEP.14 The resulting adduct, cytidylyl-2-HEP (CMP-2-HEP), was methylated 
with much higher efficiency by Fom3 than 2-HEP, forming CMP-2-HPP. To connect this new 
reaction back to the known pathway, the authors proposed a function for FomD as a hydrolase to 
remove the CMP group in preparation for the final step catalyzed by 2-
hydroxypropylphosphonate epoxidase (HppE, Fom4/Psf4 in Figure 4.1).14 
 Production of fosfomycin by Pseudomonas syringae PB-5123 was discovered in the 
1980s,15 and the self-immunity mechanism of phosphorylation was attributed to the gene product 
of psf7 (fosC).16 The entire gene cluster was located more recently using pepM,17 originally for 
the purpose of finding a homolog of Fom3 more amenable to laboratory purification and 
analysis. Surprisingly, sequencing revealed that the gene neighbors of pepM in P. syringae did 
not bear any resemblance to genes in the Streptomyces cluster, apart from hppE (Figure 4.1). 
Instead of a PnPy decarboxylase, the P. syringae cluster contains a homolog of homocitrate 
synthase, which catalyzes the addition of acetyl-CoA to PnPy in the process of forming 
phosphonomethylmalate (Pmm). This enzyme drives the PepM reaction forward via hydrolysis 
of the CoA thioester. After formation of Pmm, a series of unknown steps decreases the carbon 
backbone down to three, ultimately forming the final intermediate (S)-2-HPP. In 2012, former 
van der Donk laboratory member Dr. Seung-Young Kim and coworkers proposed a hypothesis 
based on chemical logic for this middle section of the pathway.17 According to this hypothesis, 
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hydroxylation at C1 of Pmm initiates a series of decarboxylations to yield 2-
oxopropylphosphonate (2-OPP). This proposal came from two observations, namely that 
hydroxylation at C1 of early biosynthetic intermediates had also been proposed in the 
biosynthesis of dehydrophos18 and fosfazinomycin.19 Second, the molecule 2-OPP was not a 
known physiological metabolite, but its formation had already been reported in vitro upon 
incubation of HppE with the off-pathway intermediate (R)-2-HPP.20 What remains to be 
constructed is the entire middle section of the pathway leading from Pmm to (S)-2-HPP. Since 
the introduction of this hypothesis, expression of the putative proteins in the heterologous host 
Pseudomonas aeruginosa has been attempted to improve production yield for possible genetic 
studies.17 So far, the pepM gene has been deleted to confirm its essentiality for fosfomycin 
production, but overall production of fosfomycin was very low in this heterologous system. 
Additional genetics studies would help to establish the minimal gene cluster required for 
fosfomycin biosynthesis, if a heterologous system that produces sufficient levels of fosfomycin 
can be assembled. We decided to address construction of the middle components of the pathway 
through in vitro reconstitution of the enzymes in E. coli. 
 
4.1.3 Hydroxypropylphosphonate Epoxidase: A Shared Enzymatic Step 
 The formation of the epoxide moiety of fosfomycin by HppE appears to be a shared 
mechanistic step between the Streptomyces and Pseudomonas pathways. Epoxide biosynthesis is 
generally accomplished by oxidation of an olefin by cytochrome P450 enzymes, flavin-
dependent enzymes, or Fe(II)/alpha-ketoglutarate-dependent enzymes with the epoxide oxygen 
originating from molecular oxygen.21 HppE is a member of the 2-His-1-carboxylate non-heme 
iron-dependent oxygenase family of enzymes discussed in Chapter 2, but its function is much 
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more reminiscent of a dehydrogenase. The epoxide oxygen of fosfomycin originates from the 
hydroxyl of (S)-2-HPP instead of O2, and in one proposed mechanism, the alcohol attacks a 
carbocation that forms at C1 of (S)-2-HPP (Figure 4.2).22 Successful reconstitution of HppE from 
S. wedmorensis was originally accomplished with molecular oxygen as the oxidant, along with a 
NADH/FMN reducing system to provide the additional two electrons.23 More recently, HppE 
was also found to function with H2O2 as the oxidant, with a proposed mechanism outlined in 
Figure 4.2.22  
Another intriguing feature of HppE is that the enzyme accepts the off-pathway substrate 
(R)-2-HPP, but performs a different dehydrogenation to form 2-OPP.20,24 Studies with 13C-
labeled or fluorinated analogs at C1 of (R)-2-HPP and 18O2 led to the determination that 
hydrogen atom abstraction at the C2 position is the likely path to formation of 2-OPP, compared 
to abstraction at the C1 position for fosfomycin formation.20 The activity of HppE from P. 
syringae (Psf4) has been reconstituted using the molecular oxygen reducing system with both 
(R)- and (S)-2-HPP as substrates.24 We wondered what structural differences might exist between 
Psf4 and Fom4 and whether Psf4 can also behave as a peroxidase. 
 

















































4.2 RESULTS AND DISCUSSION 
4.2.1 Bioinformatics Analysis of the Pseudomonas syringae Gene Cluster 
 In order to uncover a biosynthetic route between Pmm and (S)-2-HPP, the two 
biochemically validated intermediates in the P. syringae pathway, I performed a bioinformatic 
analysis on the unknown proteins encoded in the cluster and looked for annotations that might 
perform the reactions shown in Figure 4.1. The translated sequences of the unknown genes were 
used as queries in a BLAST® search25 to compare to the NCBI genomic database and a Phyre226 
search to look for structural similarities in the Protein Data Bank (PDB) database.27 The main 
hits are summarized in Table 4.1.  
The two hits that seemed promising were the prediction that Psf3 acts as a 
dehydrogenase/reductase, and that Psf5 may be a member of the non-heme iron-dependent 
family. Intriguingly, the main structural hit for Psf5 was HppE from Streptomyces, although Psf4 
has already been validated as an epoxidase for P. syringae. I questioned if Psf5 could be a 
duplicate vestigial enzyme in the cluster, or if it performs the hydroxylation of C1 through an 
alpha-ketoglutarate (KG)-dependent mechanism common in the non-heme iron-dependent 
family. These alpha-KG-dependent hydroxylases have a number of residues in common, such as 
a 2-His-1-carboxylate facial triad HXD/E…..H motif and a conserved Arg for interacting with 
the carboxyl of alpha-KG.28 The hydroxylases in dehydrophos and fosfazinomycin biosynthesis 
both have these residues in alignment with the well-studied taurine hydroxylase TauD. However, 
a sequence alignment that includes Psf5 reveals that it does not have a conserved Arg in the same 
position as the other enzymes, and that the facial triad of Psf5 is instead aligned with the more 
unusual HXXXE….H motif found in the other HppE enzymes.29 Assignment of Psf5 as a 
functional non-heme iron-dependent enzyme will require further investigation into possibilities 
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for its substrate and if cofactors are needed. First, I decided to investigate Psf4 and test Psf5 as an 
epoxidase.  
 
Table 4.1 Bioinformatics annotations of the P. syringae fosfomycin gene cluster. Databases 
were queried in 2013. 
Gene Product  
(from Kim et al17) 
















from P. putida 











84 24 MFS transporter 100 98 
10. Hypothetical No conserved 
domains 
N/A N/A Virus-outer capsid 
protein  
37 6 






N/A N/A N/A N/A N/A N/A 
12. HD domain protein Phosphonate 
degradation operons 
HDIG domain 
protein / HD 
phosphohydrolase 
82 / 80 39 / 36 Hydrolase, HD 
superfamily 
98 37 
13. Hypothetical Hypothetical / PHP 
domain protein 




4. Epoxidase N/A N/A N/A N/A N/A N/A 
7. Phosphotransferase Phosphotransferase 69 100 N/A N/A N/A 
8. Hypothetical Thymidylate kinase-
like protein 














FrbC 97 55 Homocitrate synthase 100 95 




98 / 94 37 / 26 Oxidoreductase, 
Epoxidase from S. 
wedmorenis 
100 91 
14. Hypothetical Dephospho-CoA 
kinase 




4.2.2 Psf4 Activity as a Peroxidase 
 Given the recent finding that HppE from Streptomyces can function as a peroxidase,22 we 
wanted to test if this holds true for the HppE from Pseudomonas. I reconstituted Psf4 in vitro 
with Fe(II) and tested its activity using (S)-2-HPP as a substrate under anaerobic conditions. The 
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reaction was initiated by the slow infusion of H2O2, as previously described for HppE,22 and 
analysis of the products by 31P NMR spectroscopy demonstrated conversion of the substrate to 
fosfomycin (Figure 4.3). A near loss of product formation was observed upon addition of 
catalase to the reaction, which scavenges the hydrogen peroxide (Figure 4.3c). Thus, like HppE, 
the Pseudomonas homolog Psf4 can function as a peroxidase.  
 
Figure 4.3 31P NMR spectroscopic analysis of the activity of Psf4 as a peroxidase. a) Activity 
assay of 50 µM Psf4 with Fe(II), 1 mM (S)-2-HPP, 1 mM H2O2, and 10 mM L-ascorbic acid, b) 
No H2O2 added, c) 5 µM catalase added, d) No Psf4 added. The top spectrum was spiked with 
authentic fosfomycin to confirm product identity. The chemical shifts of phosphonates in 31P 
NMR spectroscopy are very sensitive to pH near their pKa values, accounting for the small 




In order to understand the biochemical basis for the biosynthesis of fosfomycin by Psf4 
and its alternative function with (R)-2-HPP, we collaborated with Dr. Jonathan Chekan and Prof. 
Satish Nair (UIUC), who obtained crystal structures of P. syringae PB-5123 Psf4 in complex 
with a variety of substrates. In particular, crystallization with either (R)- or (S)-2-HPP revealed 
that bidentate binding to the metal orients each substrate for hydrogen atom abstractions leading 
to formation of a ketone or epoxide, respectively. As described earlier, this has been documented 
for S. wedmorensis HppE, where the positioning of the three carbons of the substrate in relation 
to a dioxygen mimic exposes either the hydrogens at C1 (for epoxide formation) or C2 (for 
ketone production) for abstraction.30  
 
4.2.3 Attempts to Obtain Soluble Psf5 
Psf5 is a protein of interest in the P. syringae gene cluster mainly because of its 
assignment as a putative non-heme iron-dependent protein that is predicted to be structurally 
similar to HppE (Psf4). Psf5 is also the main candidate based on bioinformatics annotations to 
perform the hydroxylation of Pmm to start the series of proposed biosynthetic steps. Initial 
attempts to express and purify Psf5 with a N-terminal His6 tag did not result in soluble protein. A 
number of expression conditions were tried, such as native expression (5 h at 30 ºC), osmotic 
stress, and heat shock. Finally, a N-terminal MBP tag was placed on Psf5, and this resulted in 
soluble protein. MBP-Psf5 was first tested as the (S)-2-HPP epoxidase, however no reaction 
occurred. Attempts to remove the tag via Factor Xa cleavage resulted in (presumably) Psf5 
precipitating out of solution or no confirmation by SDS-PAGE that the cleavage was successful. 
Future plans entailed the production of Pmm enzymatically to test as a substrate with MBP-Psf5 
and the determination if soluble Psf5 could be produced by coexpression with Psf4. In the 
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meantime, I decided to work on a late step in the proposed biosynthetic pathway and determine if 
the putative reductase Psf3 would function with 2-OPP as substrate to catalyze reduction to the 
alcohol (S)-2-HPP. 
 
4.2.4 Activity of Reductase Psf3 
 To test Psf3 activity, 2-OPP and the enantiomers of 2-HPP were obtained from the 
synthetic stock of previous van der Donk laboratory member Dr. John Whitteck. The reducing 
agent was assumed to be NAD(P)H based on the annotation of Psf3, and thus initial rates with 
each cofactor were tested by measuring decreasing absorbance at 340 nm. A 50-fold faster rate 
was observed with NADPH over NADH, implying that NADPH is the physiological cofactor 
(Table 4.2). 
 
Table 4.2 Psf3 assay to determine initial rates of NAD(P)H consumption. Assays contained 0.25 
µM Psf3, 250 µM NAD(P)H, and 4 mM 2-OPP. Error is the standard deviation calculated from 
triplicate experiments. 
Cofactor kobs (s-1) 
NADPH 3.24 ± 0.02 
NADH 0.056 ± 0.008 
 
A 31P NMR spectroscopy assay was set up to determine if 2-HPP was the product (Figure 4.4). A 
new peak appeared at around 20 ppm, which matched the 2-HPP synthetic standard. However, 
the stereochemistry of the product could not be determined through this initial assay, as (R)- and 
(S)-2-HPP would have the same chemical shift. To determine if Psf3 produces the on-pathway 
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(S)-2-HPP product, the reverse reaction was analyzed using the same 31P NMR assay with 
NADP+. Only upon incubation with (S)-2-HPP did product appear (Figure 4.4). 
 
Figure 4.4 31P NMR spectroscopic analysis of the forward and reverse reactions with Psf3. Each 
reaction contained Psf3 with a) 2-OPP and NADPH, b) (S)-2-HPP and NADP+, and c) (R)-2-
HPP and NADP+. Product identities were confirmed by spiking with authentic standards. The 
peak at 11 ppm in spectrum (a) appears to be an impurity from the 2-OPP substrate stock. 
 
4.2.5 X-ray Crystallography, Site-Directed Mutagenesis, and Kinetic Analysis of Psf3 
 With the on-pathway production of (S)-2-HPP established for the activity of Psf3, we 
opened a collaboration with Philip Olivares and Prof. Satish Nair (UIUC) to understand how the 
Psf3 active site performs its stereospecific reaction. Philip determined the 2.05 Å resolution 
cocrystal structure of Psf3 with bound ligands NADP+ and 2-OPP. The oxidized form of the 
cofactor was used to prevent catalytic turnover of 2-OPP. Psf3 is similar to members of the 3-
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hydroxyacid dehydrogenase family by both sequence and structure. The structure of Psf3 
contains an N-terminal Rossmann fold and a C-terminal helical dimerization domain. Philip 
determined that Psf3 forms homodimers in solution and in the crystal, with 2-OPP bound directly 
above NADP+ in a cleft between the two domains. 
 Our goal was to investigate how Psf3 interacts with the phosphonate and carbonyl 
moieties of 2-OPP. A Tyr/Lys pair of residues has been identified in the active sites of other 
phosphonate-binding enzymes, despite significant differences in reactions they catalyze.31 
HEPD32 (discussed in Chapter 2), HppE29 (discussed in section 4.1.3), and DhpI,33 a SAM-
dependent methyltransferase with a tripeptide phosphonate substrate, all contain a Tyr and a Lys 
in hydrogen bonding distance of the phosphonate oxygens. Similar to HEPD and HppE, the Psf3 
active site is composite, and both monomers of the homodimer contribute residues that engage 
the phosphonate group. The residue Tyr217 coming from the dimerization domain is in hydrogen 
bonding distance of a 2-OPP phosphonate oxygen atom. Instead of a Lys, Psf3 has Arg212, 
which reaches in from another monomer to cap the base of the binding site and provide 
additional interactions with a phosphonate oxygen atom. In support of the involvement of 
Arg212 in substrate interaction, I assayed a Psf3-R212K variant and showed that it has a 103-fold 
decrease in catalytic efficiency compared to WT Psf3 (Figure 4.5 and Table 4.3). For the Psf3 





Figure 4.5 The Psf3 active site and steady-state Michaelis-Menten kinetics. a) The active site of 
Psf3 cocrystallized with 2-OPP and NADP+. The green helix constitutes residues from the other 
monomer. Residues targeted for site-directed mutagenesis are highlighted. PyMOL34 was used to 
visualize the active site. b) Steady-state Michaelis-Menten kinetics curve for Psf3 WT and c) 
D242A. Error bars represent standard deviation calculated from triplicate experiments. d) 
Dependence of the rate of reduction of 2-OPP by the indicated variants on substrate 
concentration. The line for R212K was fit to pass through the origin. Error bars represent 
standard deviation calculated from triplicate experiments. 
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Table 4.3 Steady-state Michaelis-Menten kinetic parameters for Psf3 WT and D242A, and 
catalytic efficiencies of the remaining variants. 
Variant kcat (s-1) KM (mM) kcat/KM (M-1s-1) 
WT 4.4 ± 0.1 0.38 ± 0.03 (1.2 ± 0.1) x 104 
D242A 0.047 ± 0.001 0.77 ± 0.07 (6.1 ± 0.6) x 101 
T98A N/A N/A (2.6 ± 0.1) x 101 
N177A N/A N/A (4.8 ± 0.1) x 101 
R212K N/A N/A (2.4 ± 0.1) x 101 
K173A N/A N/A inactive 
 
We next investigated residues that surround the carbonyl portion of 2-OPP that may be 
responsible in stabilizing the alkoxide during hydride transfer from NADPH. Several residues 
near the carbonyl oxygen form a hydrogen bonding network with the substrate and a water 
molecule (Figure 4.5). Philip identified and performed site-directed mutagenesis to Ala on 
residues Thr98, Lys173, Asn177, and Asp242 while I prepared the proteins and performed the 
biochemical analyses to investigate their involvement in Psf3 activity by a comparison to wild-
type catalytic efficiency. The carbonyl oxygen of 2-OPP is positioned 2.4 Å from the amino 
group of Lys173, which may polarize the carbonyl for reduction to the alcohol, and/or could 
serve to protonate the alkoxide. This Lys is conserved in other 3-hydroxyacid 
dehydrogenases.35,36 Accordingly, the K173A variant did not display any significant activity 
(Figure 4.6). Ala variants of Thr98 and Asn177 could not be saturated in substrate, precluding 
the determination of kcat or KM (Figure 4.5 and Table 4.3). These variants displayed a 103-fold 
loss in catalytic efficiency. Lastly, although Asp242 is at a distance of nearly 4.6 Å from the 
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carbonyl oxygen of 2-OPP, a bridging water molecule is found in all four independent copies of 
Psf3 in the crystal structure. This water could be another candidate for protonating the alkoxide 
formed upon hydride transfer. Psf3-D242A had a 100-fold decrease in kcat compared to WT, 
supporting a role for Asp242 in catalysis. In summary, the interactions of Psf3 with 2-OPP 
observed in the X-ray structure provide a rationale for the observed stereospecificity of hydride 
transfer. Binding of the cofactor and substrate results in the orientation of the Re face of 2-OPP 
above the C4 of the nicotinamide at a distance between 2.6 - 2.7 Å. The residues that are within  
 
Figure 4.6 31P NMR spectroscopic analysis of Psf3 variants. A minor impurity of unknown 
structure remaining from the 2-OPP synthesis (chemical shift: 5.9 ppm) appears to be turned 




interaction distance to the carbonyl oxygen, and a hydrophobic pocket that houses the C3 carbon 
of the substrate control the orientation of 2-OPP, resulting in the formation of the S stereoisomer 
of the product. 
 
4.2.6 Production of Fosfomycin from Racemic 2-Hydroxypropylphosphonate 
On the basis of findings in this chapter as well as previous reports, we hypothesized that 
we could leverage the combined activities of Psf3 and Psf4 to produce fosfomycin from a 
racemic mixture of 2-HPP. In this hypothesis, Psf4 would convert (S)-2-HPP to fosfomycin, 
whereas (R)-2-HPP would be converted to 2-OPP, which in turn would be reduced to (S)-2-HPP 
by Psf3 (Figure 4.7). The net result would be comparable to a dynamic kinetic resolution, 
converting both enantiomers of 2-HPP into fosfomycin in an enantioconvergent process. Indeed, 
upon set-up of this one-pot assay, I observed complete conversion of racemic 2-HPP to 
fosfomycin (Figure 4.7). The assay was performed aerobically with Psf3 and NADPH, and the 
NADH/FMN reduction system described previously for Psf4.24 The latter conditions were 
chosen instead of using hydrogen peroxide because of incompatibility with the NADPH required 




Figure 4.7 A one-pot assay for fosfomycin production from racemic 2-HPP. a) Scheme of a 
series of reactions to produce fosfomycin that includes the activity of Psf3 and the two functions 
of Psf4 to interact with both enantiomers of 2-HPP. b) 31P NMR spectrum of the one-pot assay 
starting from a mixture of (R)- and (S)-2-HPP. The reaction was first spiked with 2-OPP to 
confirm that this intermediate was not present (given its similar chemical shift to fosfomycin), 
then further spiked with fosfomycin to confirm the identity of the product. 
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4.3 SUMMARY AND OUTLOOK 
 Fosfomycin is listed as an antibiotic of critical importance by the World Health 
Organization, because of its frequent use and its status as one of few options for treating serious 
infections.37 Certain bacteria may consider fosfomycin a critical natural product for their survival 
as well, with multiple species known to produce this compound. The discovery that some of 
these species use an almost entirely different pathway for producing the exact same molecule 
was quite unexpected, thus fueling our interest in deciphering the biosynthetic pathway in 
pseudomonads. To that end, a new step was reconstituted in the proposed pathway for the 
biosynthesis of fosfomycin in Pseudomonas syringae. 
 The current work on the reductase Psf3 established that this enzyme is capable of 
producing the on-pathway intermediate (S)-2-HPP, the key substrate for the final epoxidation to 
fosfomycin. This assignment was aided by a previously proposed biosynthetic hypothesis 
predicting that 2-OPP could be the immediate precursor to (S)-2-HPP.17 We collaborated with 
the Nair laboratory to investigate additional details about the stereospecificity of the reaction. 
Residues proposed to interact with the carbonyl and phosphonate moieties of the substrate were 
targets for site-directed mutagenesis to assess their involvement in enzyme activity. A Lys 
conserved in other 3-hydroxyacid dehydrogenase family members was deemed highly important 
for activity, while an Asp to Ala mutation resulted in a significant decrease to kcat. Additionally, 
the finding of an enzyme that converts 2-OPP to (S)-2-HPP allowed us to carry out the enzymatic 
conversion of racemic 2-HPP to fosfomycin in conjunction with the activities of Psf4. 
 The characterization of Psf3 lends support to the proposed biosynthetic pathway in Figure 
4.1. However, candidate enzymes to perform hydroxylation and decarboxylation steps still need 
to be biochemically verified. A function for Psf5 would be intriguing, since by sequence and 
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structural prediction it may be another non-heme iron-dependent enzyme that does not need 
alpha-ketoglutarate. The formation of a Psf4-Psf5 hetero-oligomer is a current hypothesis for the 
identity of an enzyme to perform the hydroxylation of Pmm. Another enzyme of interest for 
unusual chemical transformations is Psf12 (Table 4.1), which contains similarity to His-Asp 
(HD) hydrolase domain proteins. One characterized member of the HD domain family, PhnZ, is 
a diiron enzyme involved in cleaving the C-P bond of a phosphonate.38 Perhaps Psf12 shares a 
diiron catalytic center with PhnZ and could perform a challenging radical reaction not initially 
predicted in the proposed pathway. Further pathway construction would also be aided by fresh 
attempts at the heterologous production of fosfomycin in an effort to boost yields for genetic 
manipulation of the cluster. Determination of a minimal gene cluster for fosfomycin production 
and intermediates that accumulate upon individual gene deletions would be invaluable 




Restriction enzymes (NdeI, XhoI, HindIII, DpnI), Phusion® HF polymerase, and the 
Gibson Assembly® kit were purchased from New England Biolabs. Fail Safe polymerase and 
buffers were purchased from Epicentre. QIAquick PCR Purification kit and QIAprep Spin 
Miniprep kit were purchased from Qiagen. Ampicillin (100 µg/mL) was purchased from Fisher 
and GoldBio, chloramphenicol (12.5 µg/mL) was purchased from Sigma Aldrich, and isopropyl-
β-D-thiogalactopyranoside (IPTG) was obtained from IBI Scientific. Protein purification buffer 
components were purchased from Sigma Aldrich and Fisher Scientific. Lysozyme from chicken 
egg white and DNase were obtained from Sigma Aldrich, Ni-NTA resin was purchased from 
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Qiagen, and PD10 desalting columns were procured from GE Healthcare. (2S)- and (2R)-
hydroxypropylphosphonate were prepared by Dr. John Whitteck as previously described.39 
Dimethyl 2-oxopropylphosphonate, NAD(P)H, NADP+, iron ammonium sulfate, hydrogen 
peroxide, catalase from bovine liver, Chelex® 100 sodium, and fosfomycin were purchased from 
Sigma Aldrich. L-ascorbic acid was obtained from Acros Organics. D2O was purchased from 
Cambridge Isotope Labs.  
 
Table 4.4 Primers for cloning. 





































Table 4.5 Strains and plasmids. 
Name Features Source 
E. coli DH5α λpir Sup E44, ∆lacU169 
(ϕlacZ∆M15), recA1, endA1, 
hsdR17, thi-1, gyrA96, relA1, 
λpir phage lysogen 
40 
Rosetta 2 (DE3) pLysS CAMR, provides 7 rare (in E. 
coli) tRNAs for the codons 
CGG, AUA, AGG, AGA, 
CUA, CCC, and GGA in the 





Fosfomycin producing strain 
used in amplification of psf3 
and psf4 
Shionogi Co. Ltd. 
pET-15b AMPR, encodes an N terminal 
6xHis-tag® of the protein of 
interest, includes a thrombin 
recognition sequence 
Novagen 
pMAL-c2x AMPR, encodes an N terminal 
maltose binding protein 
(MBP) tag of the protein of 
interest, includes a factor Xa 
recognition sequence 
NEB 
pET15b-psf3 AMPR NdeI and XhoI 
restriction sites 
This work 
pET15b-psf4 AMPR NdeI and XhoI 
restriction sites 
This work 
pET15b-psf5 AMPR NdeI and XhoI 
restriction sites 
This work 
pMALc2x-psf5 AMPR HindIII and BamHI 
restriction sites  
This work 
pET15b-psf3 D242A AMPR NdeI and XhoI 
restriction sites 
Philip Olivares 
pET15b-psf3 T98A AMPR NdeI and XhoI 
restriction sites 
Philip Olivares 
pET15b-psf3 N177A AMPR NdeI and XhoI 
restriction sites 
Philip Olivares 
pET15b-psf3 R212K AMPR NdeI and XhoI 
restriction sites 
Philip Olivares 







4.4.2 Cloning to Produce psf3, psf4, and psf5 Expression Constructs 
Genes were amplified from the genomic DNA of Pseudomonas syringae PB-5123 with 
appropriate ends for combination with pET-15b expression vectors via Gibson assembly.41 
Briefly, genomic DNA from P. syringae PB-5123 was prepared from an overnight culture (LB, 
30 ºC) using the UltraClean® Microbial DNA Isolation Kit (Mo Bio Laboratories, Inc.) and 
following the manufacturer’s instructions. The PCR samples (50 µL) to amplify psf3, psf4, and 
psf5 contained 1X Fail Safe buffer G, 0.5 µM of each primer, 130 ng gDNA, and 0.02 U/µL 
Phusion® HF polymerase. The samples were run through the following program on a BioRad 
thermocycler: 98 ºC 30 s, 30 cycles of 98 ºC 10 s, 55 ºC 30 s, 72 ºC 1 min, then 72 ºC 5 min. 
PCR products were analyzed on a 1% agarose gel. The purified products (QIAquick PCR 
Purification Kit) were used for Gibson assembly with linear pET-15b vector or linear pMAL-c2x 
vector for psf5 (with a 2:1 insert:vector ratio, see below for linear pET-15b preparation). The 
ligation reaction (10 µL) contained 1X NEB Gibson master mix and was incubated at 50 ºC for 1 
h. An aliquot (2 µL) was used to transform E. coli DH5α electrocompetent cells. The cells 
recovered in LB for 1 h at 37 ºC and were plated onto LB/amp100 for growth at 37 ºC overnight. 
Colonies were picked for plasmid preparation (QIAprep Spin Miniprep Kit) and sequences were 
confirmed by ACGT, Inc. See pg 78, NB 3. 
Linear pET-15b was prepared by digesting the circular plasmid with NdeI and PCR 
amplifying the resulting product. The PCR sample (50 µL) contained 1X Fail Safe buffer G, 50 
µM of each primer, 20-40 ng of linear plasmid, and 0.03 U/µL Fail Safe polymerase. The sample 
was run through the following program: 98 ºC 3 min, 30 cycles of 98 ºC 10 s, 60 ºC 1 min, 72 ºC 
5 min, followed by 72 ºC 8 min. The product was treated with DpnI and purified using the 
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QIAquick PCR Purification Kit. Linear pMAL-c2x was prepared in a similar manner as 
described previously.42 
 
4.4.3 Protein Expression of Psf3 (WT and Variants), Psf4, and Psf5 
E. coli Rosetta 2 (DE3) pLysS cells (Novagen) harboring the designated plasmid were 
grown in LB supplemented with 100 µg/mL ampicillin and 12.5 µg/mL chloramphenicol while 
shaking at 37 ºC until an optical density at 600 nm of 0.6-0.8 was reached. The culture flasks 
were then placed in ice water for 10 min before induction with IPTG (0.1 mM final 
concentration). After incubation for 10-12 h at 18 ºC while shaking, the cells were harvested by 
centrifugation, and the pellet was washed with phosphate-buffered saline buffer, pH 7.4. The 
cells were resuspended in lysis buffer (Psf3 and variants: 50 mM HEPES pH 7.5, 200 mM KCl, 
20 mM imidazole, 10% glycerol; Psf4/5: 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 10 
mM imidazole, 10% glycerol), treated with 33 U DNase/mL of buffer (cells harboring Psf3 and 
variants were also treated with 1 mg/mL lysozyme), and incubated for 30 min at 4 ºC. Cell lysis 
was performed by two passages through a chilled French pressure cell (Thermo Electron 
Corporation) and the cell debris was removed by centrifugation (35,000 × g for 1 h at 4 ºC). The 
remainder of the purification procedure was performed at 4 ºC. The supernatant was first 
incubated with equilibrated Ni-NTA resin (2.5 mL resin per L overexpression culture) for 30 min 
and the flow-through was collected. The resin was washed twice with 10 column volumes of 
wash buffer (Psf3 and variants: 50 mM HEPES pH 7.5, 200 mM KCl, 50 mM imidazole, 10% 
glycerol; Psf4/5: 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 20 mM imidazole, 10% 
glycerol) and the protein was eluted off the resin with elution buffer (Psf3 and variants: 50 mM 
HEPES pH 7.5, 200 mM KCl, 250 mM imidazole, 10% glycerol; Psf4/5: 50 mM sodium 
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phosphate pH 8.0, 300 mM NaCl, 250 mM imidazole, 10% glycerol). Fractions were pooled 
based on measurement of absorbance at 280 nm on a NanoDrop spectrophotometer (Thermo 
Scientific), and the pooled fractions were concentrated to ~2 mL using an Amicon Ultra 
centrifugal filter with a 10 kDa molecular weight cut off (only for Psf3 and Psf4, as Psf5 did not 
show a clear absorbance reading). The concentrated fractions were desalted using a PD10 
column equilibrated with storage buffer (Psf3 and variants: 50 mM HEPES pH 7.5, 200 mM 
KCl, 10% glycerol; Psf4: 50 mM sodium phosphate pH 7.4, 10 mM KCl, 10% glycerol), and the 
final product was aliquoted and stored at –80 ºC. Purity was assessed by SDS-PAGE and the 
final concentration was measured by absorbance at 280 nm using a NanoDrop 
spectrophotometer. The theoretical extinction coefficient (M-1 cm-1) used for each protein was: 
22,920 for Psf3 and variants and 15,930 for Psf4 (calculated using the SIB ExPASy 
Bioinformatics Resources Portal, http://www.expasy.org).43 The same purification technique was 
used for MBP-Psf5, except the buffers for purification with amylose resin (NEB) contained 50 
mM sodium phosphate pH 7.5, 300 mM NaCl, 10% glycerol (lysis and wash), plus 10 mM 
maltose (elution). See pg 82, 116, NB 3, pg 44, 56, 160, NB 4. 
 
4.4.4 Attempts to Obtain Soluble Psf5 
Initial attempts to express and purify His6-Psf5 resulted in a possibly insoluble protein. 
Three variations of expression conditions were tried with a 100 mL trial culture of pET15b-psf5. 
A 5 mL starter culture was grown at 37 ºC for 6-7 h before 1 mL was used to inoculate the main 
culture, which grew at 37 ºC until an OD at 600 nm reached 0.9-1. A heat shock trial was 
induced with 0.1 mM IPTG and grown at 47 ºC for 20 min. An osmotic stress trial was induced 
with 0.1 mM IPTG, 500 mM sorbitol was added, and the culture grew at room temperature for 
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20 min. Both cultures then grew overnight at 18 ºC. A native expression trial was set up in a 
similar way, except a 5 mL starter culture grew overnight and the production culture grew at 30 
ºC for 5 h after induction. All trial samples were harvested by centrifugation; pellets were 
washed with 1X PBS pH 7.5, and resuspended in 20 mL of lysis buffer (see above). Lysozyme (1 
mg/mL) and DNase (90 U) were added and the solutions were incubated at 4 ºC until cells were 
homogenous. Cells were twice passed through a French pressure cell and the soluble fractions 
were collected by centrifugation (as described above). Soluble and insoluble fractions were 
analyzed by SDS-PAGE; however, very little soluble protein was observed at the correct 
molecular weight under any of the conditions. See pg 165, NB 3. 
Once MBP-Psf5 was obtained (as described in 4.4.3), attempts were made to remove the 
MBP tag prior to assaying for activity. The reaction contained 20 mM Tris-HCl pH 8.0, 100 mM 
NaCl, 2 mM CaCl2, 150 µM MBP-Psf5, and 4.4 µM Factor Xa (NEB). Aliquots were removed 
at various time points between 0 and 6 h and analyzed by SDS-PAGE. However, no band at the 
expected length of cleaved Psf5 was observed, whereas the gel showed a strong protein band at 
the size of MBP. The components for a cleavage reaction (same buffer, 1.2 µM Factor Xa) were 
then added to an assay with Fe(II)-reconstituted MBP-Psf5 (40 µM final, see 4.4.7 for procedure) 
and (S)-2-HPP substrate. A control reaction was performed with Psf4. The assays were incubated 
at room temperature for 6 h before preparation for 31P NMR analysis (see 4.4.7). Psf4 still 
produced fosfomycin and no reaction was observed for Psf5, but a precipitate formed in the Psf4 






4.4.5 Determination of Psf3 Activity by 31P NMR Spectroscopy  
The assay (500 µL) contained 50 mM HEPES pH 7.5, 30 µM Psf3 WT or variant, 2 mM 
NADPH, and 2 mM 2-OPP. The reaction was incubated at room temperature for 13 h and was 
quenched by removal of the enzyme using a Millipore centrifuge filter (10 kDa molecular weight 
cut off, 5 min, 16,000 × g). D2O (100 µL, 20% final v/v) was added to the flow-through before 
sample measurement. Reactions were performed in duplicate on an Agilent 600 MHz 
spectrometer with an OneNMR probe. Spectra were analyzed using MestReNova software 
version 8.0.0. In order to perform the reverse reaction, the assay components were the same 
except that 2 mM NADP+ and 1 mM (S)-2-HPP or (R)-2-HPP were substituted for NADPH and 
2-OPP and 15 µM Psf3 WT was used instead of 30 µM. See pg 190, 192, NB 4. 
 
4.4.6 Kinetic Characterization of Psf3 and Variants 
Experiments were performed on a Varian Cary 4000 spectrophotometer. Michaelis-
Menten parameters for Psf3 with respect to 2-OPP were determined using reactions (200 µL) 
that contained 50 mM HEPES pH 7.5, 0.25 µM Psf3 WT or 5 µM Psf3 variant, 250 µM 
NADPH, and varying amounts of 2-OPP (0.05-8 mM). Hellma® Suprasil® quartz cuvettes (1 
cm path length) were used and the change in absorbance at 340 nm was recorded. Reactions 
were performed in triplicate. Rates were measured using the Cary WinUV kinetics software 
version 6.0.0 1547 and data were fit to the Michaelis-Menten equation using Igor Pro version 
6.32A. The same reaction was also performed with varying NADPH concentrations (200 and 
350 µM) and saturating 2-OPP (4 mM). The initial rates recorded were the same as with 250 µM 
NADPH. Hence, the assay contained saturating levels of NADPH. Activity assays with WT Psf3 
were performed with either NADPH or NADH and rates were analyzed in the same way as 
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above, with the reaction containing 50 mM HEPES pH 7.5, 0.25 µM Psf3, 250 µM NAD(P)H, 
and 4 mM 2-OPP. Starts on pg 154, then pg 197, NB 4. 
 
4.4.7 Determination of Psf4 Activity by 31P NMR Spectroscopy 
Psf4 reconstitution with Fe(II) and the activity assay were performed under anaerobic 
conditions. Psf4 (200 µM) was reconstituted with 1 molar equivalent of Fe(II)(NH4)2(SO4)2 in 50 
mM HEPES pH 7.5 and incubated for 10 min prior to addition to the assay components. The 
assay mixture contained 50 mM HEPES pH 7.5, 50 µM Psf4, 1 mM (S)-2-HPP, 10 mM L-
ascorbic acid, and 1 mM H2O2 for a final volume of 500 µL. When indicated, catalase (5 µM 
final) was added. The reaction was initiated by the slow infusion of H2O2 by turning the pipet 
dial while mixing. The reaction was left for 2 h at room temperature before treatment with 
Chelex® for 20 min while shaking. Protein was removed by centrifugal filtration using a 
Millipore 10 kDa molecular weight cut off filter. D2O (100 µL, 20% final v/v) was added before 
NMR analysis. Experiments were performed in duplicate. Spectra were analyzed using 
MestReNova software version 8.0.0. See pg 183, NB 4. 
 The attempts to see activity with MBP-Psf5 were performed as with Psf4, except MBP-
Psf5 (100 µM final concentration) was reconstituted with 1 molar equivalent of 
Fe(II)(NH4)2(SO4)2, and the activity assay contained 40 µM of protein and 2 mM of (S)-2-HPP 
and H2O2. See pg 147, NB 3. 
 
4.4.8 Determination of Fosfomycin Production from Racemic 2-HPP 
The assay was performed aerobically. Psf4 (200 µM) was reconstituted with 1 molar 
equivalent of Fe(II)(NH4)2(SO4)2 in 50 mM HEPES pH 7.5 prior to addition to the assay 
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components. The assay mixture contained 50 mM HEPES pH 7.5, 100 µM Psf4, 250 µM FMN, 
1.6 mM NADH, 15 µM Psf3, 2 mM NADPH, 250 µM (S)-2-HPP, and 250 µM (R)-2-HPP for a 
final volume of 500 µL. The reaction was incubated for 2.5 h at room temperature before 
quenching and preparation for NMR analysis as described for the Psf4 activity assay. The 
reaction was repeated with (R)-2-HPP alone (500 µM) and full conversion to fosfomycin was 
again observed. See pg 203, 211, NB 4. 
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